[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS: The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther; 2008 Feb;83(2):234-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This complexity poses a challenge in translational research where genotyping is being considered as a tool to personalize drug therapy.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cluster Analysis. Cohort Studies. Dextromethorphan / metabolism. Dextromethorphan / urine. Gene Frequency. Genotype. Humans. Infant. Linear Models. Male. Middle Aged. Phenotype. Reproducibility of Results. Substrate Specificity. United States

  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827853441 for PMID:17971818 [PharmGKB] .
  • Hazardous Substances Data Bank. DEXTROMETHORPHAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Pharmacol Ther. 2008 Feb;83(2):225-7 [18202689.001]
  • (PMID = 17971818.001).
  • [ISSN] 1532-6535
  • [Journal-full-title] Clinical pharmacology and therapeutics
  • [ISO-abbreviation] Clin. Pharmacol. Ther.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1P20RR11104; United States / NIGMS NIH HHS / GM / R01GM58647; United States / NICHD NIH HHS / HD / R03 HD36783; United States / NICHD NIH HHS / HD / U10 HD031313
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7355X3ROTS / Dextromethorphan; EC / Cytochrome P-450 CYP2D6
  •  go-up   go-down

2. McNamara DR, Nafziger AN, Menhinick AM, Bertino JS Jr: A dose-ranging study of gentamicin pharmacokinetics: implications for extended interval aminoglycoside therapy. J Clin Pharmacol; 2001 Apr;41(4):374-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dose-ranging study of gentamicin pharmacokinetics: implications for extended interval aminoglycoside therapy.
  • Prolonged distribution time has been noted for high-dose (7 mg/kg) gentamicin.
  • Higher doses are used for extended-interval aminoglycoside therapy (EIA).
  • The authors investigated whether the increase in distribution time was proportional to the dose of gentamicin.
  • Twelve healthy volunteers were given low (LD, 2 mg/kg), medium (MD, 4.5 mg/kg), and high (HD, 7 mg/kg) doses of gentamicin in a randomized, crossover fashion.
  • Distribution half-life for HD (31.1 +/- 5.7 min) differed significantly (p < 0.05) from LD (22.4 +/- 6.1 min) and MD (23.8 +/- 5.1 min) with no significant difference being seen between LD and MD.
  • This study verifies that when using EIA dosing with HD gentamicin, sampling within 90 minutes after the beginning of the infusion provides information that leads to overestimation of peak serum concentration/minimum inhibitory concentration and inaccurate calculation of pharmacokinetic parameters.
  • [MeSH-major] Anti-Bacterial Agents / pharmacokinetics. Anti-Bacterial Agents / therapeutic use. Gentamicins / pharmacokinetics
  • [MeSH-minor] Adolescent. Adult. Area Under Curve. Creatinine / blood. Cross-Over Studies. Dose-Response Relationship, Drug. Female. Half-Life. Humans. Immunoassay. Infusions, Intravenous. Male. Metabolic Clearance Rate. Middle Aged. Time Factors. Urinalysis

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11304893.001).
  • [ISSN] 0091-2700
  • [Journal-full-title] Journal of clinical pharmacology
  • [ISO-abbreviation] J Clin Pharmacol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Gentamicins; AYI8EX34EU / Creatinine
  •  go-up   go-down

3. Angelopoulou MK, Vassilakopoulos TP, Siakantaris MP, Kontopidou FN, Boussiotis VA, Papavassiliou C, Kittas C, Pangalis GA: EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin's disease. Leuk Lymphoma; 2000 Mar;37(1-2):131-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin's disease.
  • To evaluate the efficacy of EBVD combination chemotherapy followed by low dose (LD) involved field (IF) radiation therapy (RT) in patients with clinical stage (CS) I-IIA Hodgkin's disease (HD), we analyzed 148 patients treated in our Unit from March 1988 to November 1995.
  • All drugs were administered i.v. at days 1 and 15, every 4 weeks, for a total of 4-6 cycles.
  • LDIF RT (24-32 Gy) was scheduled for patients with complete response (CR) or >90% reduction of tumor load, after EBVD.
  • Patients with stable or progressive disease (SD, PD) after EBVDx3 or poor compliance to the regimen received mantle or inverted Y RT at standard dose.
  • Nine patients relapsed at a median of 7 months from the end of treatment.
  • Six patients have died so far; 5 of HD and one of stroke.
  • One patient developed a diffuse large cell lymphoma 48 months after the diagnosis of HD.
  • We conclude that EBVD followed by LDIF RT is a highly effective regimen for patients with CS I-IIA HD.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Combined Modality Therapy. Dacarbazine / administration & dosage. Epirubicin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Remission Induction. Survival Analysis. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10721777.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; EBVD protocol
  •  go-up   go-down

4. Murphy JA, Savage CM, Alpard SK, Deyo DJ, Jayroe JB, Zwischenberger JB: Low-dose versus high-dose heparinization during arteriovenous carbon dioxide removal. Perfusion; 2001 Nov;16(6):460-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to compare low-dose (LD) and high-dose (HD) systemic heparinization in a prospective randomized study of arteriovenous carbon dioxide removal (AVCO2R) during acute respiratory distress syndrome, using a commercially available heparin-coated oxygenator.
  • Adult sheep (n = 13) received an LD50 smoke inhalation and 40% TBSA third degree cutaneous flame burn injury.
  • At 40-48 h post-injury, animals underwent cannulation of the carotid artery and jugular vein and were then randomized to HD heparin (activated clotting time, ACT > 300s, n = 6) and LD heparin (ACT < 200s, n =7) and placed on AVCO2R for approximately 72 h using an oxygenator with the Trillium Bio-Passive Surface.
  • Mean ACTs were significantly different, as expected (HD: 446 +/- 26s, LD: 213 +/- 12s, p < 0.05).
  • AVCO2R shunt flow averaged approximately 13% of cardiac output with mean CO2 removal similar in HD and LD, p = NS.
  • In conclusion, LD systemic heparin (ACT < 200s) with a heparin-coated oxygenator does not increase thrombogenicity during AVCO2R for smoke/burn-induced severe lung injury in sheep.
  • [MeSH-minor] Acute Disease. Animals. Arteriovenous Shunt, Surgical / methods. Arteriovenous Shunt, Surgical / standards. Blood Flow Velocity / drug effects. Coated Materials, Biocompatible. Disease Models, Animal. Dose-Response Relationship, Drug. Female. Fibrinogen / drug effects. Fibrinogen / metabolism. Oxygenators, Membrane / standards. Platelet Count. Respiratory Insufficiency / complications. Respiratory Insufficiency / therapy. Sheep. Treatment Outcome. Whole Blood Coagulation Time

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • Hazardous Substances Data Bank. HEPARIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11761085.001).
  • [ISSN] 0267-6591
  • [Journal-full-title] Perfusion
  • [ISO-abbreviation] Perfusion
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coated Materials, Biocompatible; 142M471B3J / Carbon Dioxide; 9001-32-5 / Fibrinogen; 9005-49-6 / Heparin
  •  go-up   go-down

5. Daminov BT, Raimkulova NP: [Effects of simvastatin therapy on the lipid blood spectrum and nitric oxide in patients with chronic glomerulonephritis]. Lik Sprava; 2008 Oct-Dec;(7-8):57-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of simvastatin therapy on the lipid blood spectrum and nitric oxide in patients with chronic glomerulonephritis].
  • 100 patients with different types of glomerular disease were divided in two groups depending on the treatment scheme: Group B received the traditional therapy, Group A patients received traditional therapy + 20 mg Simvastatin per day.
  • Nitric oxide radicals, NADPF-diaphorase, nitrate reductase, acetylcholinesterase enzymes, as well as total cholesterol, triglycerides, HD, LD, VLD lipoproteins concentration were assessed initially and after three month treatment.
  • It was revealed that the treatment with statins taking into account types of dislipidemia could have an additional renoprotective effect in the patients with different types of chronic glomerular disease.

  • Genetic Alliance. consumer health - Glomerulonephritis.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. SIMVASTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19663018.001).
  • [ISSN] 1019-5297
  • [Journal-full-title] Likars'ka sprava
  • [ISO-abbreviation] Lik. Sprava
  • [Language] RUS
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Hypolipidemic Agents; 0 / Lipids; 31C4KY9ESH / Nitric Oxide; AGG2FN16EV / Simvastatin
  •  go-up   go-down

6. Nelles G, Schmitt L, Humbert T, Becker V, Sandow P, Bornhoevd K, Fritzsche D, Schäuble B, TOPMATMIG-0001 investigators: Prevention of episodic migraines with topiramate: results from a non-interventional study in a general practice setting. J Headache Pain; 2010 Feb;11(1):33-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of patients with migraine headaches are treated in non-specialized institutions though data on treatment outcomes are largely derived from tertiary care centers.
  • Reasons for discontinuation included adverse events (2.1%), lost to follow-up (1.8%), other reasons (1.5%), and end of therapy (0.3%) though in the majority of patients who discontinued no reasons were listed.
  • [MeSH-major] Fructose / analogs & derivatives. Migraine Disorders / prevention & control. Neuroprotective Agents / therapeutic use
  • [MeSH-minor] Absenteeism. Adolescent. Adult. Aged. Analgesics, Opioid / therapeutic use. Drug Administration Schedule. Dysmenorrhea / drug therapy. Electronic Health Records. Family Practice. Female. Follow-Up Studies. Humans. Male. Middle Aged. Outcome Assessment (Health Care). Pain Measurement / methods. Prospective Studies. Quality of Life. Surveys and Questionnaires. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Migraine.
  • Hazardous Substances Data Bank. TOPIRAMATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Headache. 2009 Nov-Dec;49(10):1454-65 [19804392.001]
  • [Cites] Cephalalgia. 2009 Oct;29(10):1021-7 [19735529.001]
  • [Cites] Headache. 2001 Jul-Aug;41(7):638-45 [11554951.001]
  • [Cites] Headache. 2001 Jul-Aug;41(7):646-57 [11554952.001]
  • [Cites] Cephalalgia. 2002 Apr;22(3):209-21 [12047461.001]
  • [Cites] CNS Drugs. 2002;16 Suppl 1:13-8 [12196035.001]
  • [Cites] Headache. 2002 Nov-Dec;42(10):984-99 [12453030.001]
  • [Cites] JAMA. 2004 Feb 25;291(8):965-73 [14982912.001]
  • [Cites] Cephalalgia. 2003 Dec;23(10):961-2 [14984228.001]
  • [Cites] Arch Neurol. 2004 Apr;61(4):490-5 [15096395.001]
  • [Cites] J Neurol. 2004 Aug;251(8):943-50 [15316798.001]
  • [Cites] Headache. 1991 May;31(5):333-40 [1830566.001]
  • [Cites] Arch Neurol. 1995 Mar;52(3):281-6 [7872882.001]
  • [Cites] Cephalalgia. 1996 Feb;16(1):11-21 [8825694.001]
  • [Cites] Neurol Clin. 1997 Feb;15(1):125-41 [9058401.001]
  • [Cites] Arch Intern Med. 1999 Apr 26;159(8):813-8 [10219926.001]
  • [Cites] Neurol Sci. 2004 Oct;25 Suppl 3:S244-5 [15549548.001]
  • [Cites] Am J Med. 2005 Mar;118 Suppl 1:3S-10S [15841882.001]
  • [Cites] Int J Clin Pract. 2005 Aug;59(8):961-8 [16033621.001]
  • [Cites] Headache. 2006 Jul-Aug;46(7):1151-60 [16866719.001]
  • [Cites] Expert Rev Neurother. 2006 Aug;6(8):1147-57 [16893343.001]
  • [Cites] Clin Ther. 2006 Jul;28(7):1002-11 [16990078.001]
  • [Cites] Mayo Clin Proc. 2006 Oct;81(10):1311-9 [17036556.001]
  • [Cites] Neurology. 2007 Jan 30;68(5):343-9 [17261680.001]
  • [Cites] J Occup Environ Med. 2007 Mar;49(3):252-7 [17351510.001]
  • [Cites] Headache. 2007 Mar;47(3):355-63 [17371352.001]
  • [Cites] Headache. 2007 Apr;47(4):500-10 [17445099.001]
  • [Cites] J Headache Pain. 2007 Apr;8(2):90-3 [17221343.001]
  • [Cites] Lancet Neurol. 2007 Dec;6(12):1054-62 [17988947.001]
  • [Cites] Lancet Neurol. 2008 Apr;7(4):354-61 [18339350.001]
  • [Cites] Neurology. 2008 Apr 22;70(17):1555-63 [18427072.001]
  • [Cites] Acta Neurol Taiwan. 2008 Jun;17(2):132-48 [18686655.001]
  • [Cites] Cephalalgia. 2008 Sep;28 Suppl 2:1-8 [18715326.001]
  • [Cites] Cephalalgia. 2008 Oct;28(10):1003-11 [18727647.001]
  • [Cites] Headache. 2008 Nov-Dec;48 Suppl 3:S124-30 [19076658.001]
  • [Cites] Neurol Clin. 2009 May;27(2):321-34 [19289218.001]
  • [Cites] Clin Ther. 2009 Mar;31(3):542-59 [19393844.001]
  • [Cites] Mayo Clin Proc. 2009 May;84(5):422-35 [19411439.001]
  • [Cites] Acta Neurol Scand. 2009 Aug;120(2):80-7 [19432934.001]
  • [Cites] Neurology. 2000;55(9 Suppl 2):S46-52 [11089519.001]
  • (PMID = 19894100.001).
  • [ISSN] 1129-2377
  • [Journal-full-title] The journal of headache and pain
  • [ISO-abbreviation] J Headache Pain
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Neuroprotective Agents; 0H73WJJ391 / topiramate; 30237-26-4 / Fructose
  • [Other-IDs] NLM/ PMC3452185
  • [Investigator] Wegner T; Fischer HW; Wolfram B; Schindlbeck K; Peters S; Schax U; Dietz EM; Haas J; Föh M; Katholnigg D; Rauch G; Kühn M; Becker VU; Springer M; Auner GM; Hontzek K; Kaune HW; Schreibmüller V; Liadski S; Wiedeking B; Rengeling M; Henning V; Walaschewski B; Schätzl RJ; Steinbrück B; Reineke H; Rönnebeck S; Armbruster T; Schätzl RJ; Tiedt A; Hördt T; Eisenkrätzer F; Waldmann R; Sandow P; Metzger B; Eckert A; Kayali N; Lang M; Klein H; Böneke H; Schiel C; Eyck M; Gross HD; Beck A; Spengruber B; Schulz-Meentzen M; Gruber A; Rubbel-Ehle A; Porrmann B; Unger M; Schaps KP; Stienker-Fisse H; Meyer G; Matuschke A; Eckardt H; Jansen U; Klook K; Witteborn M; Roidl T; Farke-Rämer K; Dietlein M; Möller P; Hofmann W; Lederle S; Wiedemann F; Rieser U; Wimmer ML; Enderle C; Gottesbüren D; Weber T; Oberling M; Flöhl W; Martinovic N; Köller W; Jersch B; Adam H; Carstensen O; Franke K; Martini N; Schneider-Nutz H; Bek E; Magnus-Ellenbroek B; Kukowski B; Jorns U; Kelch T; Endrass G; Katzfuss R; Schmitt L; Kühn F; Schietsch HJ; Diery HD; Wiese-Junginger D; Guse-Grosse F; Thonack J; Franz P; Dauwe R; Gerbaulet U; Koller S; Freitag E; Krug R; Jonas B; Linke A; Ulmer A; Jakob S; Gillwald V; Tomm M; Ampatziadis N; Udosic J; Kossler-Wiesweg C; Brose KO; Westfal HP; Noveanu RD; Jacob C; Fuchs V; Althen A; Lang A; Lebmeier R; Beykirch KF; Müller S; Krehan G; Ivancic R; Eichhorn A; Lion F; Misera A; Nowack C; Wagner A; Böger M; Ries S; Hachenberg K; Pickert P; Lang M; Strick V; Lüdtke A; Siemer M; Setiawan S; Feuerstack G; Müller A; Kim-Giesemann S; Noack D; Unsorg B; Busch R; Weischer K; Stenzel C; Albrecht C; Assmann U; Wegner M; Hufnagel H; Loddo M; Lohse LD; Derissen W; Junge B; Seidel F; Bannies H; Hanoldt I; Bachus R; Burger-Deinerth E; Ha-Phuoc H; Gülbeyaz M; Brauer G; Leps W; Ahrari F; Lode S; Brandt C; Zimmermann R; Böhme A; Bruckhaus-Walter M; Phillipp U; Loel U; Bruch M; Schulze K; Kohl SC; Lakony R; Nesimi M; Zug HD; Scarel S; Schultheiss UG; Berdermann-Welz S; Freudenstein W; Schmitt R; Christopher A; Patzelt U; Augustin-Reuss D; Sigel KO
  •  go-up   go-down

7. Clark AD, Douglas KW, Mitchell LD, McQuaker IG, Parker AN, Tansey PJ, Franklin IM, Cook G: Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment. Br J Haematol; 2002 Jun;117(3):605-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment.
  • A phase I-II study of high-dose (HD) alkylating agents in newly diagnosed patients with multiple myeloma after maximum response to Z-Dex (idarubicin, dexamethasone) therapy and DHAP (cisplatin, HD cytosine arabinoside, dexamethasone), stem cell mobilization is reported.
  • Twenty-six patients, median age 56 years (range 42-66), completed Z-Dex chemotherapy and peripheral blood stem cells (PBSC) were mobilized with DHAP.
  • Patients then preceded to cyclophosphamide (HD Cy: 6 g/m(2)) with granulocyte colony-stimulating factor followed by busulphan-melphalan-conditioned PBSC autograft.
  • Interferon alpha was introduced at 3 months post transplant as maintenance therapy.
  • Median time from diagnosis to transplantation was 8 months (range 6-12).
  • Median time from DHAP to HD-Cy was 6 weeks (range 4-12) and from HD-Cy to transplant was 8 weeks (range 6-12).
  • On an intent-to-treat basis, the response rates were three complete response (CR, 12%), 21 partial response (PR, 80%) and two stable disease (SD, 8%) post Z-Dex, five CR (19%) and 21 PR (81%) post HD-Cy, and 14 CR (54%) and 12 PR (46%) post transplant.
  • The treatment-related mortality (TRM) was 4% (1 patient).
  • DHAP produces effective PBSC mobilization and sequential HD therapy, including autologous PBSCT, in patients who received Z-Dex; this offers significant durable disease response rates with acceptable TRM.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Multiple Myeloma / drug therapy
  • [MeSH-minor] Adult. Aged. Busulfan / administration & dosage. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Hematopoietic Stem Cell Mobilization / methods. Hematopoietic Stem Cell Transplantation. Humans. Idarubicin / administration & dosage. Interferon-alpha / administration & dosage. Male. Melphalan / administration & dosage. Middle Aged. Recombinant Proteins. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Br J Haematol 2002 Sep;118(4):1201
  • (PMID = 12028028.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; 99210-65-8 / interferon alfa-2b; G1LN9045DK / Busulfan; Q20Q21Q62J / Cisplatin; Q41OR9510P / Melphalan; ZRP63D75JW / Idarubicin; DHAP protocol
  •  go-up   go-down

8. Veitenhansl M, Stegner K, Hierl FX, Dieterle C, Feldmeier H, Gutt B, Landgraf R, Garrow AP, Vileikyte L, Findlow A, Waterman C, Boulton AJ, Shankhdhar K, Shankhdhar L, Shankhdhar U, Petrova NL, Foster AV, Edmonds ME, Ferraresi R, Caravaggi C, De Giglio R, Cavaiani P, Pogliaghi I, Sommariva E, Katz IA, Harlan A, Miranda-Palma B, Prieto-Sanchez L, Armstrong DG, Bowker JH, Mizel MS, Cernea S, Wohlgelernter J, Kidron M, Modi P, Raz I, Arbit E, Nosek L, Kapitza C, Beckett P, Gelfand R, Goldberg M, Heise T, Testa MA, Turner RR, Hayes JF, Scranton RE, Simonson DC, Yang YW, Hsu YJ, Naujok O, Francini F, Jörns A, Tiedge M, Lenzen S, Abdel-Wahab YH, Marenah L, Orr DF, Shaw C, Flatt PR, Chokkalingam K, Mansell PI, Clausen P, Ekbom P, Damm P, Feldt-Rasmussen U, Nielsen B, Mathiesen ER, Feldt-Rasmussen B, Dewan S, Da Silva N, Ternan PM, Leong KS, Wilding JP, Asatiani N, Kurashvili R, Dundua M, Shelestova E, Pagava K, Ramazashvili M, Hod M, Smirnov S, Petersen JL, Justesen TI, Ringholm Nielsen L, Müller C, Højlund K, Wensaas A, Kase ET, Aas V, Rustan AC, Thoresen GH, Levin K, Beck-Nielsen H, Gaster M, Im SS, Kang SY, Kim SY, Ahn YH, Lihn AS, Schmoll D, Werner T, Kienitz A, Meyer M, Barthel A, Ailett F, Sutherland C, Walther R, Grempler R, Sasson S, Reich R, Tenenbaum T, Alpert E, Anfossi G, Russo I, Traversa M, Massucco P, Mattiello L, Doronzo G, Trovati M, Lally S, Tan CY, Owens D, Tomkin GH, Porchay I, Péan F, Bellili N, Betoulle D, Balkau B, Tichet J, Marre M, Fumeron F, Group D.E.S.I.R., Chatellier G, Alhenc-Gelas F, DIABHYCAR Study Group, Nichols GA, Brown JB, Hayes RP, Bowman L, Drexel H, Saely CH, Marte T, Benzer W, Langer P, Hoefle G, Moll W, Aczel S, Karagiannis E, Lübben G, Urquhart R, Edwards G, Bruce S, Howlett HS, Cugnardey N, Turner KC, Park JS, Fiedorek FT, Avogaro A, Gallo A, Pinton P, Rizzuto R, Murphy E, Ceolotto G, Caterson I, Guy-Grand B, Hill J, Barone M, Aiello A, Allochis G, Borzì V, Cannatà F, Caronna S, D'Avanzo A, Elli R, Formoso G, Paroli A, Scardapane R, Sorichetti P, Tatti P, Viviani G, Santeusanio F, Italian Repaglinide Study Group, Manzella D, Grella R, Abbatecola AM, Paolisso G, Søndergaard LG, Monster TB, Johnsen SP, Olsen ML, McLaughlin JK, Sørensen HT, Lervang HH, Rungby J, Lyssenko V, Fredriksson J, Almgren P, Anevski D, Orho-Melander M, Sjögren M, Tuomi T, Groop L, Jaziri R, Aubert R, Tuomilehto J, Hu G, Jousilahti P, Peltonen M, Lindstrom J, Laina A, Alevizaki M, Philippou G, Souvatzoglou A, Anastasiou E, Alba S, Metcalf BS, Voss LD, Jeffery AN, Wilkin TJ, Glüimer C, Colagiuri S, Vistisen D, Borch-Johnsen K, Haynes A, Bower C, Bulsara MK, Jones TW, Davis EA, Mortensen HB, Hougaard P, Holl R, Swift P, Pociot F, Knip M, Hansen L, Szadkowska A, Pietrzak I, Zmysłowska A, Wyka K, Bodalski J, Holl RW, Swift R, Hougaard R, Gerstl EM, Engelsberger I, Rabl W, Rosenbauer J, Gröbe H, Hofer SE, Krause U, DPV-Wiss-Study Group, Dabelea D, Morgan T, Pettitt DJ, Dolan L, Mayer-Davis EJ, Pihoker C, Hillier TA, Imperatore G, Ruggiero A, Hamman RE, Stylianou A, Tentolouris N, Perrea D, Tselepis AD, Lourida E, Kitsou E, Katsilambros N, Vedovato M, Dodesini AR, Lepore G, Tiengo A, Trevisan R, Penno G, Miccoli R, Pucci L, Lucchesi D, Bandinelli S, Fotino C, Triscornia S, Baldassari E, Del Prato S, Reboldi P, Santeusanio E, Fuller J, Langham RG, Gow RM, Zhang Y, Kelly DJ, Christensen PK, Parving HH, Gilbert RE, Chibalin AV, Zhong Z, Kotova O, Davidescu A, Ehrén I, Ekberg K, Wahren J, Wassef L, Buckley AJ, Rooney KB, Briody J, Thompson M, Ozanne SE, Thompson CH, Chamson-Reig A, Summers K, Arany EJ, Hill DJ, Solerte SB, Gazzaruso C, Locatelli E, Precerutti S, Schifino N, Ferrari E, Fioravanti M, Phenekos CV, Ginis A, Fragaki I, Chalkiadaki M, Tzioras C, Powell LA, McGuire GM, Jewhurst V, Trimble ER, Rasmussen BM, Vessby B, Uusitupa M, Berglund L, Pedersen E, Riccardi G, Rivellese AA, Tapsell L, Hermansen K, KANWU Study Group, da Silva Xavier G, Rutter J, Rutter GA, Briaud IM, Lingohr MK, Dickson LM, McCuaig JR, Lawrence JC, Rhodes CJ, Wikstrom JD, Katzman SM, Shirihai OS, Yang J, Deng S, Wang X, Hessner MJ, Wu J, Wong RK, Sukumvanich S, Markman JF, Naji A, Wolf BA, Gao Z, Rubi B, Del Arco A, Satrústegui J, Maechler P, Del Guerra S, Lupi R, Bugliani M, Sbrana S, Torri S, Boggi U, Vistoli F, Mosca F, Marchetti P, Rennings AJ, Smits P, Stewart MW, Tack CJ, Li L, Nyström T, Gutniak M, Ahrén B, Holst J, Sjöholm Å, Gomes MB, Cailleaux S, Tibiriça E, Albertini JP, Chen H, Mather R, Valensi PE, Chisalita SI, Arnqvist HJ, Kraenkel N, Adams V, Linke A, Gielen S, Schuler G, Humbrecht R, Cipollone F, Iezzi A, Fazia M, Pini B, Cucurullo C, De Cesare D, Schmidt AM, Mazurek T, Zang LF, Mannion J, Diehl J, Martin J, Martella A, Zalewski A, Shi Y, Otter W, Winter M, Doering W, Standi E, Schnell O, Kragelund C, Køber L, Faber J, Hildebrandt P, Steffensen R, Pankowska E, Szypowska A, Lipka M, Herwig J, Scholl-Schilling G, Böhles H, Robertson KJ, Schönle E, Gucev Z, Mordhorst L, Tamer SC, Gall MA, Ludvigsson J, Hoogma RP, Hammond PJ, Gomis R, Kerr D, Bruttomesso D, Bouter P, Wiefels KJ, de la Calle H, Schweitzer DH, Pfohl M, Torlone E, Krinelke LG, 205-Nations Study Group, Conget I, Storms F, Rodriguez J, Leperlier C, Davies M, AT.LANTUS Study Group, Peter R, Luzio SD, Dunseath G, Miles A, Hare B, Backx K, Pauvaday V, Owens DR, Caselli A, Marfia GA, Battista C, Veves A, Spallone V, Uccioli L, Gonzalez JS, Peyrot MF, Rubin RR, Leventhal H, Scheffler N, Ulbrecht JS, Cavanagh PR, Boulton AJ, Perrin NA, Oglesby A, Bastyr EJ, Ziegler D, Siekierka-Kleiser E, Meyer B, Schweers M, Selvarajah D, Wilkinson ID, Emery CJ, Shaw PJ, Griffiths PD, Tesfaye S, Obrosova IG, Arezzo J, Phillips K, Fidarestat Study Group, Gribble FM, Williams L, Reimann F, Iakoubov R, Whiteside C, Brubaker PL, Acitores A, González N, Sancho V, Valverde I, Villanueva-Peñacarrillo ML, Martín-Duce A, Trigo MV, Arnés L, Burkart V, Ichino N, Ohashi A, Klein BS, Paxian S, Schmid R, Karlsen AE, Heding PE, Frobøse H, Rønn SG, Kruhøffer M, Ørntoft TF, Nerup J, Mandrup-Poulsen T, Billestrup N, Cardozo AK, Ortis F, Feng YM, Rasschaert J, Van Eylen F, Storling J, Herchuelz A, Eizirik DL, Wang H, Kouri G, Wollheim CB, Ribaux P, Hammar E, Parnaud G, Rouiller D, Bosco D, Halban P, Midthjell K, Carlsson S, Grill V, Lau C, Færch K, Glümer C, Tetens I, Jørgensen T, Tillin T, Forouhi N, McKeigue P, Chaturvedi N, Zethelius B, Hales CN, Berne C, Coleman RL, Stevens RJ, Holman RR, Christensen JO, Sandbæk A, Lauritzen T, Irwin N, Gault VA, Green BD, Harriott P, O'Harte FP, Bouman SD, Ursø B, Brand CL, Rolin B, Ribel U, Schäffer L, Maggs DG, Ceriello A, Frias JP, Wang Y, Ruggles JA, Kolterman OG, Piconi L, Weyer C, Want LL, Ratner RE, Uwaifo GI, Thornberry NA, Eiermann G, Kim D, Lankas G, Leiting B, Li Z, Lyons K, Petrov A, Sinha Roy R, Woods A, Woods J, Zhang BB, Fisher M, Moller DE, Weber AE, Dreyer M, Bellin C, Schmitz V, Roesen R, Nescheret AP, Bose AK, Mocanu MM, Carr RD, Yellon DM, Manolopoulos K, Born S, Wagner A, Jeziorska M, Ben Drief A, Bashir M, Tomlinson D, Malik RA, Zeymer U, Schwarzmaier-D'Assie A, Petzinna D, Chiasson JL, Stratton IM, Af Björkesten CG, Fagerudd J, Rosengård-Bärlund M, Forsblom C, Pettersson-Fernholm K, Waden J, Saraheimo M, Rönnback M, Thorn L, Groop PH, Mollsten A, Svensson M, Kockum I, Rudberg S, Brismar K, Dahlquist G, Hovind P, Hansen TK, Tarnow L, Thiel S, Jensen BR, Flyvbjerg A, Kankova K, Hertlova M, Krusova D, Schwenke S, Ott J, Thom SA, Mistry P, Sjolie A, Larsen B, Witt N, Hughes AD, Samira HH, Lahiry S, Howlader SR, Parveen S, Azad Khan AK, Clarke PM, Gray A, Stevens R, Holman R, Phillips L, Phillips PJ, Chittleborough C, Baldock K, Taylor A, North West Adelaide Health Study Team, Davis WA, Davis TM, Knuiman MW, Hendrie D, Worthley D, Nicolucci A, Pellegrini F, De Berardis G, Franciosi M, Belfiglio M, Rossi MC, Sacco M, Valentini M, Richardson CC, Jones P, Persaud S, Hussain K, Clark A, Christie MR, Gniuli D, Hribal ML, Accili D, Khan M, Zervou S, Cheung L, Abouna S, Ifandi V, Pelengaris S, Luco RF, Ferrer J, Ma D, Shield JP, Dean W, Leclerc I, Knauf C, Burcelin R, Kelsey G, Powers AC, Shostak A, Ferrara N, Poffenberger G, Jerome WG, Brissova M, Geloneze SR, Tambascia MA, Pareja JC, Chaim E, Silveira HV, Geloneze B, Ravikumar B, Carey PE, Snaar JE, Dheelchand D, Cook DB, Neely D, Taylor G, Morris PG, Taylor R, Stears AJ, Masding MG, Wootton SA, Sandeman DD, Klimes I, Wein S, Gasperikova D, Ukropec J, Wiernsperger N, Sebokova E, Manco M, Mingrone G, Granato L, Greco AV, Nanni G, Castagneto M, Vidal H, Calvani M, Ferrannini E, Alvarsson M, Sundkvist G, Lager I, Henricsson M, Berntorp K, Fernqvist-Forbes E, Steen L, Örn T, Shutler S, Bianchi-Biscay M, AT:LANTUS Study Group, Rosenstock J, Sugimoto D, Strange P, Stewart J, Soltes Rak E, Dailey G, Kloos C, Müller U, Sämann A, Femerling M, Risse A, Jecht M, Haak T, Garg R, Lawrence IG, Akinsola MO, Davies MJ, McNally PG, Garber AJ, Kim H, Draeger E, Aydın L, Şengül A, Kürklü A, Uçak S, Basat O, Seber S, Altuntaş Y, Jin J, Yu Y, Yu H, Zhang X, Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, Knight D, Oakley D, Tan M, Sato A, Nagao M, Aki N, Nakagami T, Iwamoto Y, Zhou Z, Li X, Huang G, Yan X, Yang L, Peng J, Wang J, Tan S, Tang W, Fürnsinn C, Brunmair B, Wagner L, Gras F, Artwohl M, Zierhut B, Waldhäusl W, Shine BL, Hopkins D, Anand V, Lim E, Raval U, Sharp P, Corder R, Lipkin D, Lahiri A, Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyörälä K, Simoons ML, Standl E, Soler-Soler J, Öhrvik J, Euro Heart Survey Investigators, Bruce DG, Starkstein SE, Schauer UJ, Astrup AS, Pietraszek L, Nielsen FS, Rossing P, Ali S, Smidt UM, Yokoyama H, Pavkov ME, Knowler WC, Bennett PH, Nelson RG, López-Alba A, Morcillo L, Caballero A, Montoya L, Jiménez A, Maceira B, Lewis JB, Ravid M, Wajman A, Tadgell C, Remuzzi G, Hunsicker LG, Wadén J, Wessman M, Taskinen MR, FinnDiane Study Group, Pugliese G, Amadio L, Menini S, Oddi G, Ricci C, Iacobini C, Pricci F, Sorcini M, Pesce C, Migliaccio E, Giorgio M, Pelicci P, Di Mario U, Lassila M, Jandeleit-Dahm K, Seah KK, Calkin AC, Allen TJ, Cooper ME, Lopes de Faria JM, Cavakcanti TC, Silva KC, Ferrari AL, Lopes de Faria JB, Cellek S, Foxwell NA, Cotter MA, Cameron NE, Tennagels N, Jordan H, Stahl P, Voss MD, Welte S, Werner U, Lehmann R, Moeschel K, Baumgartner F, Oeckinghaus A, Beck A, Weigert C, Hennige A, Schleicher ED, Häring HU, Müssig K, Staiger H, Häring HU, Natalicchio A, Laviola L, De Tullio C, Renna L, Giorgino R, Giorgino F, Falasca M, Maffucci T, Park D, Kang S, Song J, Lee D, Lee Y, Hariharan N, Kunselman L, Gu L, Sasseville V, Harrity T, Cheng PT, Pratley RE, Schweizer A, Mills D, Ahren B, Kim TH, Song XL, van Poelje PD, Potter SC, Dang Q, Fujitaki JM, Linemeyer DL, Landau BR, Erion MD, Pankop M, Golay A, Després J, Sjöström L, Lawlor DL, Legg KT, Ur E, Houweling ST, Kleefstra N, Meyboom-de Jong B, Bilo HJ, Schlömer GJ, Meyer G, Kasper J, Mühlhauser I, Young B, Taylor J, Friede T, Hollis S, Mason J, Long A, Gambling T, Pauline L, Burns E, New J, Gibson M, Betteridge DJ, Leiter LA, AUDIT Investigators, Whitty PM, Eccles MP, Hawthorne G, Grimshaw J, Steen IN, Vanoli A, Wood L, Speed C, McDowell D, Rewers M, Maahs D, Wadwa R, Eckel R, Tracy R, Pfützner A, Strotmann HJ, Schulze J, Hohberg C, Pahler S, Forst T, Ambery PD, Sydall H, Cooper C, Dennison E, Sayer AA, Barker D, Phillips D, Lalic NM, Ostojic M, Lalic K, Zamaklar M, Jotic A, Ilic M, Rajkovic N, Lukic L, Milicic T, Vergès B, Zeller M, Steg PG, Beer JC, Brisard C, Brindisi MC, Dentan G, Laurent Y, Janin-Manificat L, Makki H, Ravisy J, Cottin Y, Ajjan RA, Grant PJ, Futers TS, Brown JM, Carter AM, Rasmussen MS, Bruun JM, Pedersen SB, Richelsen B, Dietze-Schroeder D, Sell H, Koenen M, Eckel J, Delporte ML, Bauche IB, Brichard SM, Ait El Mkadem S, Rezsohazy R, Tsiotra PC, Tsigos C, Gatsiou C, Raptis SA, Walker CG, Bryson JM, Hancock DP, Caterson ID, Takahashi N, Hatakeyama H, Kasai H, Gauthier BR, Iezzi M, Fukuda M, Duhamel DL, Ravier MA, Düfer M, Neye Y, Krippeit-Drews P, Hennige AM, Sausbier U, Arntz C, Sausbier M, Neuhuber W, Ruth P, Drews G, Beauvois MC, Rolland JF, Jonas JC, Merezak C, Henquin JC, Gilon P, Jabin Gustafsson A, Dzabic M, Islam MS, Vaxillaire M, Cheyssac C, Dina C, Vasseur-Delannoy V, Leprêtre F, Siddiq A, Froguel P, Neve B, Fernandez-Zapico ME, Ashkenazi-Katalan V, Urrutia R, Melloul D, Froguel R, Poulsen P, Wojtaszewski J, Richter E, Vaag A, Granhall C, Renström E, Luthman H, Isomaa B, Gloyn AL, Edghill EL, Pearson ER, Mackay DJ, Temple IK, Noyes K, Freedenberg D, Gillespie KM, Lambert AP, Gale EA, Ellard S, Hattersley AT, Fanelli CG, Porcellati F, Rossetti P, Busciantella NR, Billi C, Burrin DG, Bolli GB, Bingham EM, Dunn J, Sutcliffe-Goulden J, Marsden P, Amiel S, Davis RE, Kennedy-Martin T, Peters JR, Wittrup-Jensen KU, McEwan P, Morrissey M, Currie CJ, Akram K, Pedersen-Bjergaard U, Thorsteinsson B, Pibernik-Okanovic M, Peros K, Begic D, Szabo S, Metelko Z, Vlaiculescu MV, Calota I, Busila T, Bruckner I, Giannakopoulou DF, Lindner HD, Hrachovinova T, Fejfarova V, Csémy L, Malcomson J, Campbell M, Pandolfi A, Giardinelli A, Di Tomo P, Di Silvestre S, Di Fulvio P, Capani F, Consoli A, Roesen P, Patruno A, Grilli A, Capani R, Felaco M, Boner G, McCarroll K, Brenner BM, de Zeeuw D, Kowey P, Shahinfar S, Crow RS, Iso K, Kuboki K, Tada H, Yoshino G, Schjoedt KJ, Andersen S, Distiller LA, Degenhardt TP, Szabo JR, Khalifah RG, Schotzinger RJ, Achenbach P, Knopff A, Naserke H, Ziegler AG, Bonifacio E, Valera L, Jardin B, Roche S, Lampasona V, Pugniere M, Roquet F, Granier C, Laune D, Afifiyan F, Cheung R, Yantha J, Jackowski G, Dosch HM, Nakanishi K, Kogawa N, Komatsu Y, Fontés G, Imamura T, Ilic C, Puech C, Ktorza A, Bataille D, Dalle S, Sørensen H, Fosgerau K, Gelling RW, Nishimura E, Andersen B, Madsen P, Lau J, Streicher R, Wagner K, Vettermann R, Potterat O, Renard E, Panteleon AE, Kolopp M, Rebrin K, Steil G, Steil GM, Hariri F, Darwin C, Saad MF, Buckingham B, Kunselman B, Wong L, Istoc E, Leach J, Purvis R, Monfre SL, Fischer JS, Garg S, Ahmann AJ, Ruchti TL, Gandhi GY, Nuttall GA, Mullany CJ, Schaff HV, Williams BA, Rizza RA, McMahon MM, Gates G, Mentel J, Smith R, Crook J, Hosszúfalusi N, Vatay Á, Palik È, Füst G, Karádi I, Romics L, Pánczél P, Aurich K, Voelker U, Braun A, Müller UA, Nguyen LL, Kriketos AD, Hancock D, Denver GS, Üceyler N, Schütt M, Lesch KP, Mössner R, Sommer C, Seda O, Liska F, Kazdova L, Sedova L, Krenova D, Zima T, Tremblay J, Kren V, Hamet P, Klöting N, Follak N, Klöting I, Dessapt C, Dei Cas A, Baradez MO, Hayward A, Thomas S, Viberti G, Gnudi L, Gale CP, Jandeleit-Dahm KA, Thallas V, Thomas MC, Candido R, Burns WC, Forbes JM, Shymanskyy I, Kuchmerovska T, Klimenko A, Jaeckel E, Manns MP, von Boehmer H, Hedrich HJ, Téllez N, Montolio M, Estimes E, Rodríguez-Mulero S, Soler J, Montanya E, Liu Y, Chen J, Rowlands D, Chan H, Simeonov IS, Anthony K, Bingham E, Marsden PK, Amiel SA, Malik RJ, Zelaya F, Williams S, Brammer M, Mountjoy PD, Bailey SJ, Shaw JE, Sicree R, Dunstan D, Cameron A, Zimmet PZ, Hewitt S, Graff-Iversen S, Assah FK, Fezeu L, Kengne A, Awah PK, Mbanya JN, Shu JA, Kamadjeu RK, Kiawi EC, Mbanya J, Assah F, Kerényi Z, Péterfalvi A, Bosnyák Z, Madarász E, Tabák ÁG, Szánthó J, Rákóczi I, Tamás G, Di Bartolo P, Valpiani G, Di Martino M, Scaramuzza A, Saragoni S, Degli Esposti E, Cannatá F, Gudbjornsdottir S, Cederholm J, Nilsson P, Eliasson B, Miettinen ME, Miettinen J, Nan HR, Dong Y, Gao W, Sun B, Wang N, Fu F, Shi H, Ding M, Lorenzo C, Serrano-Ríos M, Martínez-Larrad MT, González-Sánchez JL, Seclén S, Villena A, Gonzalez-Villalpando C, Williams K, Stern MP, Haffner SM, Sakurai M, Miura K, Kita Y, Takamura T, Ota T, Ishizaki M, Morikawa Y, Nakagawa H, Szybiński Z, Szurkowska M, Mardarowicz G, Łopatyński J, Gilis-Januszewska A, Szafraniec K, Nicer T, Kwon HS, Lee JH, Lee HJ, Park YM, Choi YH, Kim SR, Jang SA, Song BR, Yoon KH, Kim HS, Lee WC, Cha BY, Lee KW, Son HY, Kang SK, Jørgensen ME, Moustgaard H, Bjerregaard P, Ebara F, Dunstan DW, Salmon J, Owen N, Cameron AJ, Welborn TA, Armstrong T, Jolley D, Galtier F, Deschamps V, Borys JM, Lasfargues G, Andre P, Born C, Royer B, Wilpart E, Cailleau M, Eschwege E, Timar RZ, Serban V, Vlad AR, Diaconu LF, Rosu M, Olari O, Sima AC, Qiao Q, Chappuis B, Diem P, Christ ER, Iafusco D, Prisco F, Gemma C, Mattera S, Sanges M, Menneila C, Sommese L, Jarosz-Chobot P, Polanska J, Feltbower RG, McKinney PA, Stephenson CR, Bodansky HJ, Icks A, du Prel JB, Grabert M, Giani G, Kyvik KO, Skytthe A, Ioacara S, Farcasiu E, Bradescu O, Guja C, Scutaru G, Savu O, Ionescu-Tirgoviste C, Ola TO, Hawa MI, Buzzetti R, Scherbaum W, Kolb H, Thivolet C, Hunter S, Hadden D, Guntram S, De Leiva A, Mauricio D, Pozzilli P, Leslie RD, Benediktsson R, Jonsdottir AM, Einarsdottir AS, Reynisdottir I, Aspelund T, Grant SF, Thorleifsson G, Sigurdsson G, Stefansson K, Gudnason V, Wollitzer AO, Jovanovic L, Lobo PE, Martí ML, Preiti MC, Urdaneta RF, Juarez SS, Schober E, Thon A, Rami B, Hofer S, „DPV-Wiss-Study Group“, Tringham JR, Buyukbese MA, Sakamoto Y, Inoue Y, Matsumoto H, Oono K, Tokumasa Y, Gorter KJ, Janssen PG, Stolk RP, van Hessen PA, Rutten GE, Palik É, Niedermayer D, Murro A, Geloneze S, Coghi C, Federici MO, Benedetti MM, Koehler C, Henkel E, Temelkova-Kurktschiev T, Stier U, Ott P, Siegert G, Bergmann S, Hanefeld M, Leonhardt W, Sayeed MA, Mahtab H, Khanam PA, Banu A, Rashid MA, Mulnier H, Seaman H, Lovell D, Soedamah-Mathu S, Colhoun H, Lawrenson R, Diehm C, Lange S, Darius H, Pittrow D, Haberl R, von Stritzky B, Tepohl G, Allenberg JR, Trampisch HJ, Soinio M, Marniemi J, Laakso M, Lehto S, Rönnemaa T, Ito C, Sasaki H, Ishida S, Maeda R, Barengo NC, Lakka TA, Köhler C, Benke I, Raccah D, Bailleau C, Vexiau P, Vaur L, Aydin N, Topsever P, Filiz TM, Dayan A, Bulgurlu S, Gebeloglu N, Demirtunc R, Dagar A, Skliros E, Sotiropoulos A, Vassibosis A, Xipnitos C, Liva E, Chronopoulos I, Merkouris P, Skourtis S, Pappas S, Charbonnel B, Baigts F, Dumenil V, Paillasson S, Baleydier A, Hanaire H, Sert C, Chabrier G, Rodier M, Fontaine P, Kim JI, Miyake Y, Sakai T, Takamatsu K, Tomioka Y, Sugano H, Murao S, Shimizu I, Unwin NC, Nag S, Roglic G, Connolly V, Roper N, Goodwin J, Kelly W, Lervang HH, Thomsen RW, Hundborg HH, Schønheyder HC, Khalangot MD, Gang H, Tajima N, Bianchi C, Giovannitti MG, Pellegrini G, Caricato F, Bertolotto A, Corfini M, Guzder R, Gatling W, Byrne C, Varillas VF, Boronat M, Carrillo A, La Roche F, Ojeda A, López Y, Marrero D, Nóvoa J, Shahidul Alam Khan AK, Thaware PK, Gangat I, Howlett TA, Jenum AK, Holme I, Birkeland KI, Sourij H, Stoschitzky K, Klein W, Roth M, Dittrich P, Wascher TC, Hilding A, Eriksson AK, Agardh EE, Efendic S, Östenson CG, Levitt NS, Bradshaw D, Salzsieder E, Freyse EJ, Rutscher A, Heinke P, Augstein P, Makino H, Kainou Y, Konoue E, Ohno K, Ebisui O, Fujii Y, Kondo S, Fujiyama M, Tanaka K, Takemoto K, Kida K, Onuma Y, Osawa H, Tuomilehto-Wolf E, Kinnunen L, Laine AP, Kokko T, Kakko T, Hermann R, Veijola R, Simell O, Ilonen J, Guglielmi C, Galgani A, Beretta Anguissola G, D'Avola D, Bakhtadze E, Weiss H, Hedrich HJ, Wedekind D, Bilbao JR, San Pedro JI, Vitoria JC, Martul P, Castaño L, Badenhoop K, Ramos Lopez E, Usadel KH, Wägner AM, Cloos PA, Stahlhut M, Bergholdt R, Ramos E, Taxvig C, Vella A, Smyth D, Cooper JD, Undlien DE, Rønningen KS, Ionescu-Tîrgovişte C, Savage DA, Dunger DB, Strachan DP, Ring SM, Todd JA, Mironczuk K, Kretowski A, Kinalska I, Nutland S, Guja L, Nielsen LB, Gammeltoft S, Schwarz PE, Towers WG, Fischer S, McRae JF, Willis JA, Scott RS, Potter HC, Merriman TR, Frampton CM, George PM, Spranger J, Möhlig M, Hoffmann K, Müller S, Osterhoff M, Ristow M, Boeing H, Pfeiffer AF, Li Y, Fisher E, Burwinkel B, Schrezenmeir J, Mager U, Pulkkinen L, Lindi V, Lindström J, Xiu LL, Sui Y, Weng JP, Kalis M, Cilio CM, Olde B, Owman C, Groop LC, Levéen P, Da Ros R, Assaloni R, Maier A, Quagliaro L, Zuodar G, Zakja E, Gu HF, Nordman S, Brookes AJ, Prince JA, Helwig U, Rubin D, Hampe J, Schreiber S, Fölsch UR, Döring F, Porzio O, Massa O, Cunsolo V, Hansen T, Njolstad PR, Terrinoni A, Melino G, Federici M, Colombo C, Federici G, Barbetti F, Herder C, Bongardt F, Schöpfer A, Rathmann W, Martin S, Holle R, Thorand B, Wichmann HE, Koenig W, Illig T, KORA Group, Blasiak J, Arabski M, Krupa R, Wozniak K, Dabrowski J, Kasznicki J, Zurawska M, Drzewoski JS, Kose H, Matsumoto K, Wilke B, Kerr-Bayles LJ, Walder K, Civitarese A, Jowett J, Curran J, Elliott K, Trevaskis J, Bishara N, Wanyonyi S, Sanigorski AM, Zimmet P, Blangero J, Kissebah A, Collier GR, Carlsson E, Arner P, Ridderstråle M, Nitz I, Lindner I, Suzuki S, Hinokio Y, Hirai M, Yamada T, Yoshizumi S, Tanizawa Y, Matsutani A, Ishihara H, Takahashi K, Katagiri H, Oka Y, Nam M, Hong SB, Kim HJ, Ahn CW, Kim YS, Lee HC, Zeggini E, Parkinson J, Groves CJ, Frayling TM, Hitman GA, Walker M, Sampson M, Levy JC, Weedon MN, Wiltshire S, Owen KR, Halford S, McCarthy MI, Shehadeh N, Bakri D, Gershoni-Baruch R, Yasuda K, Okada T, Sunaga Y, Kajimoto Y, Shibasaki T, Kaburagi Y, Kadowaki T, Estalella I, Rica I, Vazquez JA, Spanish Group of MODY (GEM), de Andrade P, van den Ouweland JM, Maassen JA, Huoponen K, Savontaus ML, Dimitrijevic Sreckovic VS, Djordjevic PB, Popovic SS, Gostiljac D, Canovic F, Sreckovic BM, Colak E, Obrenovic R, Milic G, Glisic B, Etemadi A, Saadat N, Azizi F, Tsur A, Cohen Y, Yerushalmi Y, Wainstein J, Israel Diabetes Research Group (IDRG), Norberg M, Eriksson JW, Lindahl B, Andersson C, Rolandsson O, Stenlund H, Weinehall L, Lecomte PJ, Vol S, Cacès E, Chabrolle C, Halimi JM, Nijpels G, Dekker JM, Bouter LM, Heine RJ, Löbner K, Mollenhauer U, Baumgarten A, Com E, Sargin M, Karadeniz S, Sengul A, Suleymanoglu Y, Pekcanli N, Yilmaz T, Cicero AF, Dormi A, Miconi A, D'Addato S, Laghi L, Brillante R, Bernardi R, Grandi E, Gaddi AV, Jones M, Lacey L, Bergenheim K, Yamagata F, Yamakoshi M, Takahashi M, Kawazu S, Festa A, Hanley AJ, Otvos JD, Goff DC, Wajngot A, Cerasi E, Baumert J, Schneider A, Löwel H, Roussel R, Müller-Brandes C, Ballmann M, Nährlich L, Thalhammer G, Nastoll M, Schwarz J, Johne U, Erfurth M, Lüddeke HJ, Liebl A, Kotowa W, Maclaine G, Evers T, Pontiroli AE, Pizzocri P, Paganelli M, Folli F, Lee K, Jung DS, Park MK, Henriksen JE, Durck TT, Rasmussen M, Weghuber D, Roden M, Tura A, Pacini G, Bischof M, Widhalm K, Sharp GW, Shanmugam G, Straub SG, Michael D, Chow R, Regazzi R, Gerona R, Martin TF, Waselle L, Tomas A, Min L, Pessin JE, Halban PA, Björklund A, Ma Z, Portwood N, Parton LE, Smith ER, Diraison F, Tsuboi T, Lehtihet M, Webb DL, Honkanen RE, Knoch KP, Meisterfeld R, Bergert H, Kolpe M, Altkrüger A, Saeger HD, Solimena M, Haspel D, Aguilar-Bryan L, Bryan J, Ullrich S, Berchtold S, Ranta F, Seebohm G, Alexander D, Wulff P, Kuhl D, Lang F, Speier S, Yang SB, Rose T, Rupnik M, Varadi A, Mitchell KJ, Schwappach B, Bleck C, Wienbergen A, Rustenbeck I, Vieira E, Gylfe E, Seissler J, Wohlrab U, Schmiegelt D, Ruetter R, Herten M, Lechner A, Nolan AL, Blacken RA, Habener JF, Gao R, Ustinov J, Korsgren O, Mikkola M, Lundin K, Otonkoski T, Jahr H, Bieback K, Kern S, Brendel C, Brendel MD, Bretzel RG, Taniguchi S, Ohgawara H, Tsuchiya K, Tsuchiya M, Okochi H, Kelter AR, Dohrmann C, Austen M, Aicher B, Maedler K, Schumann DM, Iwakura Y, Donath MY, Peter A, Opel A, Seufert J, Fernández E, Serradas P, Martín MA, Plachot C, Bailbé D, Gangnerau MN, Gavete ML, Fajardo S, Escrivá F, Portha B, Álvarez C, Lipsett M, Jamal AM, Hanley S, Castellarin M, Rosenberg L, Bhushan A, Georgia S, Calderari S, Gangnerau MN, Meile MJ, Miettinen PJ, Palgi J, Virkamäki A, Ferris WF, Campbell SC, Armstrong L, Hole N, Lako M, Macfarlane WM, Barbera A, Altirriba J, Nadal B, Larsen MO, Gotfredsen CF, Holst JJ, Reusens B, Sparre T, Kalbe L, Leunda A, Kruhoffer M, Orntoft T, Remade C, daSilva Xavier G, Motakis E, Nason GP, Leibiger B, Berggren PO, Leibiger IB, Uhles S, Moede T, Welters HJ, Senkel S, Erdmann S, Thomas H, Morgan NG, Irminger JC, Rickenbach K, Donath M, Rouiller DG, Taylor JP, Jackson DA, Chan SL, Dezaki K, Watanabe M, Hosoda H, Kangawa K, Yada T, Kühnen P, Laubner K, Hernández R, Silvestre RA, Egido EM, Châtenet D, Leprince J, Chartrel N, Vaudry H, Marco J, Zhang F, Zhang Q, Tengholm A, Thore S, Costes S, Longuet C, Broca C, Baltrusch S, Dyachok O, Thams P, Anwar MR, Capito K, Radu RG, Fujimoto S, Mukai E, Shimono D, Nabe K, Shimodahira M, Kominato R, Aramaki Y, Yamada Y, Seino Y, Giroix MH, Agascioglu E, Courtois P, Malaisse WJ, Sener A, Piquer S, Barcelo-Batllori S, Julia M, Li J, Li XJ, Lou M, Zhang J, Zhou Q, Zhao GZ, Webb GC, Dalal S, Garcia C, Saxena P, Houk M, Nenquin M, Abdel-Ghany M, Miele C, Romano C, Corbo V, Maitan MA, Andreozzi F, Ungaro P, Oriente F, Raciti GA, Formisano P, Beguinot F, McClenaghan NH, McCluskey JT, Patterson S, Efanov A, Sewing S, Bokvist K, Gromada J, Frederiksen AL, Juhl CB, Schwarts M, Schmitz O, Andersen PH, Valeri C, Castelli MD, Bonfante R, Beyan H, Elouil H, Khaldi MZ, Evangelista S, Zeender E, Berney T, Schumann D, Franklin I, Sergeev P, Chervonsky AV, Wollheim C, Nyblom H, Ahmed M, Bergsten P, Sol ER, Kharroubi I, Ladriere L, Cnop M, Moffitt JH, Fielding B, Currie J, Staiger K, Brandhorst D, Winter D, Kellerer M, Oprescu AI, Naassan A, Klimentova T, Constantin SA, Tang C, Uchino H, Lam L, Wheeler MB, Fantus GI, Giacca A, Ortsäter H, Sundsten T, Youshikawa H, Winzell MS, Montrone C, Martemucci S, Perrini S, Caccioppoli C, Størling J, Grassetti D, Scipioni A, Dotta F, Yamamoto N, Tsunekawa S, Ito Y, Oiso Y, Miura Y, Niki I, Scrocchi LA, Ha KB, Wang F, Chen Y, Wu L, Fraser PE, Yermen B, Lilla V, Kaminski A, Mathe Z, Dupraz P, Zbinden M, Filo A, Bucher P, Rinsch C, Thorens B, Pepper MS, Estilles E, Sigrist S, Rieger L, Mandes K, Bohbot A, Pinget M, Kessler L, Parab PB, Katdare MR, Galande S, Saha B, Yoshida A, Satoh J, Homo-Dekarche F, Coulaud J, Durant S, Drexhage HA, Mabley JG, Deb A, Wallace R, Pacher P, Elder RH, Szabo C, Schlosser M, Mentel R, Moya-Suri V, Wassmuth R, Gürtler L, Ankelo M, Westerlund A, Blomberg K, Hinkkanen AE, Popova VV, Gruzov MA, Afanasyeva VV, Kulikovskaya AV, Melnichenko SV, Mankovsky BN, Zak KP, Koczwara K, Warncke K, Kawasaki E, Imagawa A, Uchigata Y, Kobayashi M, Abiru N, Yamasaki H, Eguchi K, Chrul S, Polakowska E, Heinrich A, Walter M, Pitocco D, Visalli N, Crinò A, Costantino F, Manfrini S, Spera S, Suraci C, Patera P, Matteoli MC, Schiaffini R, Ghirlanda G, Leotta S, IMDIAB Group, Hatziagelaki E, Tsiavou A, Degiannis D, Chaidaroglou A, Manginas A, Koniavitou K, Desai M, Williams AJ, Horton VA, Bingley PJ, Cull CA, Citarrella R, Richiusa P, Mattina A, Criscimanna A, Mantione L, Bronte V, Pizzolanti G, Galluzzo A, Giordano C, Giulietti A, Stoffels K, Overbergh L, Mathieu C, Bilgic S, Aktas E, Salman F, Yillar G, Yilmaz M, Deniz G, Valorani GM, G. IMDIAB, Pozzilli R, Weets I, Truyen I, Verschraegen I, Van der Auwera B, De Schepper J, Dorchy H, Lebrethon MC, Van Gaal L, Van Rooy P, Pipeleers DG, Gorus FK, Belgian Diabetes Registry (Brussels, Belgium), Shtandel SA, Atramentova LA, Karachentsev YI, Kravchun NA, Koval SN, Poltorak VV, Levchenko TP, Snegurakaya IA, Miloslavskiy DK, Bojko VV, Resnik LA, Chico A, Rojas I, Julià M, Novials A, Bendlová B, Včelák J, Vaňková M, Šrámková D, Šamalíková P, Kvasničková H, Vondra K, Petrone A, Vania A, Zavarella S, Alemanno I, Di Cola S, Ribaudo MC, Leonetti F, Angel B, Carrasco E, Santos J, Albala C, Oyarzún A, Pérez-Bravo F, Petry CJ, Ong KK, Michelmore K, Artigas S, Wingate DL, de Zegher F, Ibáñez L, Prestle J, Adomeit A, Hammer E, Zieher T, Missler B, Appl T, Schindler M, Brodbeck K, Machicao F, Häring H, Just M, Færgeman N, Knudsen J, Quint M, Tschank G, Korn M, Henriksen EJ, Dokken BB, Sloniger JA, Dörig J, Quarré L, Piatkiewicz P, Taton J, Czech A, Gorski A, Jebens E, Brennesvik EO, Ktori C, Ruzzin J, Shepherd PR, Jensen J, Lakka HM, Rankinen T, Leon AS, Skinner JS, Wilmore JH, Rao DC, Bouchard C, Vendrell JJ, Chacon MR, Garcia-España A, Fernandez-Real J, Gutierrez C, Richart C, Takeshita Y, Shimizu A, Hamaguchi E, Kaneko S, Hřebíček J, Orel M, Lichnovská R, Gwozdziewiczová S, Chlup R, Faturos I, Tournis S, Fotinakis P, Thomakos P, Manousaki M, Leontsini D, Taxildaris K, Mitrakou A, Kim S, Hur K, Shim W, Ahn C, Cho Y, Lim S, Kim K, Lee H, Cha B, Beregszaszi M, Chevenne D, Sebag G, de Kerdanet M, Huet F, Polak M, Lacombe D, De Paoli A, Levy-Marchal C, Mokhort T, Shishko E, Shepelkevich A, Benito M, Arribas M, Valverde AM, Menghini R, Marchetti V, Cardellini M, Sbraccia P, Lauro D, Lauro R, Ali AT, Penny C, van der Merwe MT, Paiker JE, Psaras G, Ekram F, Crowther NJ, Musri MM, Corominola H, Casamitjana R, Párrizas M, Renström F, Burén J, Park C, Park Y, Lee G, Kang E, Kim KS, Sanchez-Margalet V, Gonzalez-Yanes C, Diaz-Troya S, Rodriguez de Fonseca F, McNamara MR, Boschetti N, Schmid D, Spinas GA, Trüb T, Niessen M, Kuhlmann J, Neumann-Haefelin C, Belz U, Juretschke HP, Kramer W, Herling AW, Markova I, Oliyarnyk O, Cahova M, Manders RJ, Koopman R, Zorenc AH, Keizer HA, van Loon LJ, Straczkowski M, Kowalska I, Dzienis-Straczkowska S, Nikolajuk A, Gorska M, Zabielski P, Baranowski M, Gorski J, Tack CJ, de Haan J, Klomp D, Heerschap A, Corpeleijn E, Budzinski RM, Stengele I, Schuler M, Selzle N, Lehmann-Lintz T, Heckel A, Vavrinkova H, Meskhishvili E, Furier SM, Parkes HA, Cooney GJ, Alemzadeh R, Tushaus KM, Nencioni S, Giovannitti G, Longo V, de Vries R, Kerstens MN, van Tol A, Dullaart RP, McBride R, Denke MA, Pearson T, Battisti WP, Brady WE, Palmisano J, Tuzova OV, Wahl HG, Hong Q, Luz K, Xu G, Schmülling RM, Liebich HM, Oomen PH, Hattori H, Smit AJ, Scheek LM, Thomaseth K, Lajoix AD, Gauthey A, Dietz S, Jahannault C, Manteghetti M, Petit P, Gross R, Ostenson CG, Quynh NT, Florén A, Langel U, Gedulin BR, Smith P, Prickett KS, Tryon M, Barnhill S, Yeoh T, Young AA, Hiles R, Carpenter T, Serota D, Schafer K, Ross P, Nelson D, Rebelatto M, Ikeda H, Nagashima K, Tsukiyama K, Todo T, Trombetta M, Boselli L, Calì A, Cretti A, Monauni T, Bifari F, Bonora E, Muggeo M, Bonadonna RC, Gredal C, Rosenfalck A, Dejgaard A, Hilsted J, Vankova M, Sramkova D, Samalikova P, Vcelak J, Kvasnickova H, Bendlova B, Rudovich NN, Rochlitz HJ, Ritzel RA, Butler AE, Butler PC, Murphy MJ, Körner A, Csillag J, Pintér Á, Cameron N, Toman M, Gray IP, Vielwerth SE, Rinnov A, Jensen RB, Juul A, Uitterlinden P, Bruining GJ, Lamberts SW, Rasmussen E, Malis C, Ekstrom C, Arne A, James JL, Thomas P, Cavan DC, Owona AM, Ozaki R, So W, Tong P, Chan M, Wong G, Cockram C, Chan J, Redemann NH, Götz B, Lahm P, Mader G, Tadayyon M, Oh Y, Schippmann V, Kluge R, Bornstein SR, Scherbaum WA, Joost HG, Bae HY, Kim SY, Lee BR, Vertigan H, Carroll D, Griffiths L, Coghlan MP, Freeman S, Toffolo G, Dalla Man C, Basu R, Rizza R, Cobelli C, Bertoldo A, Price J, Mathis CA, Mason NS, Holt D, Kelley C, Mckolanis TM, Kelley DE, Whyte M, Jackson N, Beale R, Treacher D, Carroll P, Jones RH, Umpleby M, Jaquet D, Boiko J, Rigal O, Czernichow P, Lévy-Marchal C, Qvisth V, Hagström-Toft E, Moberg E, Bolinder J, Sjöstrand M, Gudbjörnsdottir S, Strindberg L, Lönnroth P, Mick DD, Sumarac-Dumanovic M, Cvijovic GM, Kendereski A, Pejkovic D, Zoric S, Casanueva FF, Dieguez CC, Singh RJ, Basu A, Chittilapilly EG, Johnson MC, Abdallah BM, Shubeska Stratrova S, Svendsen OL, Dhatariya KK, Bigelow ML, Nair KS, Lundgren M, Rüge T, Myrnäs T, Gimeno RE, Suri V, Li D, Huard C, Martinez R, Vettore M, Sironi AM, Gastaldelli A, Mari A, Ciociaro D, Buzzigoli E, Pettiti M, Positano V, Lombardi M, Radziuk J, Pye S, Brehm AR, Krssak M, Bernroider E, Anderwald C, Nowotny P, Cline G, Shulman GI, Kotsa K, Papazisi A, Spanopoulos I, Giovos I, Suzuki A, Sobajima H, Naruse S, Kitagawa M, Ishiguro H, Futakuchi S, Goto H, Hines G, Kennedy I, Matthews D, Levy J, Radikova Z, Koska J, Ksinantova L, Imrich R, Huckova M, Vigas M, Wallace TM, Matthews DR, Rajala U, Hiltunen L, Keinänen-Kiukaanniemi S, Noh JH, Kim DJ, Choi NH, Lee BW, Chung JH, Min YK, Lee MS, Kim KW, Lee MK, Byrne CD, Holt HB, Phillips DI, Wood PJ, Darekar AA, Astrup A, Gross S, Matthies K, Weck M, Malinska H, Beifort RS, Berria R, DeFronzo R, Cusi K, Gorshunska MY, Karachenzev YI, López-Bermejo A, Pratt KL, Hwa V, Recasens M, Broch M, Vendrell J, Rosenfeld RG, Fernández-Real JM, Ricart W, Grunnet L, Pedersen BK, Franke B, Fleming S, Lemke N, Laue C, Pfeuffer M, Lecube A, Hernández C, Genescà J, García L, Francisco G, Simó R, Kraml PJ, Syrovatka P, Brunerova L, Smejkalova V, Potockova J, Andel M, Leshchenko Z, Poltorack V, Krasova N, Gladkih A, Yang K, Chamson A, Thyssen SM, Rojo Llobet AM, Christoffersen BØ, Raun K, Fledelius C, Svendsen O, Vinterby A, Golozoubova V, Afonso RA, Ribeiro RT, Macedo MP, Guarino MP, Yang G, Kurita S, Misu H, Akahori H, Cerf ME, Nkomo XI, Muller CJ, Du Toit DF, Louw J, Wolfe-Coote SA, Nikishin P, Zagayko A, Taylor KD, Guo X, Langefeld CD, Cur J, Jinagouda S, Bowden D, Hokanson J, Rotter JI, Liew CF, Wise SD, Yeo KP, Teng CH, Lee KO, Fisher FM, Trujillo ME, Hanif W, McTernan PG, Barnett AH, Scherer PE, Kumar S, Kaltenbach S, Stumvoll M, Mlynarski W, Zmyslowska A, Andrzejewski W, Shojaee-Moradie F, Das S, Stolinski M, Jefferson W, Cramb R, Shahmanesh M, Lyngsø D, Simonsen L, Bülow J, Meinardi JR, Sluiter WJ, Wolffenbuttel BH, Bonnet F, Guebre-Egziabher F, Rabasa R, Laville M, Gosby AK, Maloney CA, Haering HU, Patarrao RS, Lautt WW, Correia NC, Santos AI, Leite V, Boavida JM, NanWei TN, Bobbioni-Harsch E, Lehmann T, Sztajzel J, Morel P, Huber O, Chassot G, Assimacopoulos-Jeannet F, Gedulin G, Baron A, Hendrickx H, Lane J, Coverly J, Simcox J, Stocks J, Brown L, Beha A, Juretschke P, Gerl M, Klebach M, Biemer-Daub G, Pérez-Del-Pulgar S, Zorzano A, Heinsbroek AC, d'Alessio D, van Dijk G, Tornero MP, Bailey CJ, Mack CM, Wilson JK, Parkes DG, Kusunoki M, Sakakibara F, Kato K, Okabayashi N, Nakamura T, Miyata T, Habu S, Nakamura R, Nakasone Y, Yasaka T, Ishihara R, Morikawa R, Otake K, Nakaya Y, Ruzickova J, Rossmeisl M, Flachs P, Sponarova J, Prazak T, Matejkova O, Kopecky J, Gram DX, Liu W, Bödvarsdóttir T, Hansen JB, Sturis J, Kern W, Hallschmid M, Benedict C, Schultes B, Born J, Fehm HL, Westerbacka J, Lammi K, Häkkinen AM, Rissanen A, Yki-Järvinen H, Mayr P, Mertl-Roetzer M, Lauster F, Pohl M, Lerch M, Haslbeck M, Eriksen J, Rahlfs VW, Serhiyenko VA, Serhiyenko AA, Serhiyenko LM, Radulian G, Vladica M, Panaite C, Balas B, Derosa G, Dumas A, Fiorito A, Prieto PG, Cancelas J, Loba J, Czupryniak L, Bialasiewicz P, Pawlowski M, Nowak D, Dupuy O, Le Berre JP, Bordier L, Rousseau C, Mayaudon H, Bauduceau B, Bossi AC, Meregalli G, Balini A, Berzi D, Cremonesi B, Cerrato D, Rezzani C, Tumiati M, Han K, Min K, Kim E, Ahn K, Ahn H, Argüelles I, Forga L, Izquierdo M, Gorostiaga E, Fuentes C, Ibáñez J, Rivero A, Baynes K, Pentecost C, Bell JD, Thomas EL, Jackson NC, Umpleby AM, Kuhl J, Ruderman NB, Musi N, Goodyear LJ, Patti ME, Thorell A, Nygren J, Ljungkvist O, Degerblad M, Ståhle A, Brismar TB, Saha AK, Båvenholm PN, Aydemir D, Kiran B, Unal M, Okumus N, Kayserilioglu A, Perkins J, Kıran B, Ünal M, Salman S, Yıllar G, Özer E, Kayserilioǧlu A, Yılmaz T, Dinççaǧ N, Tikkanen H, Lakka T, Macdonald AL, Harrison M, Dickinson H, Bone AJ, Watt PW, Østergård T, Short K, Saltin B, Nair K, Di Mauro M, Papalia G, Battiato R, Giuffrida D, Boemi G, Castellino P, Akter S, Akhter A, Pervin T, Ahmed S, Ahmed KR, Saleh F, Chaudhury HS, Tankova T, Dakovska G, Lazarova M, Dakovska L, Kirilov G, Koev D, Torgerson JS, Hauptman J, Boldrin M, Shi YF, Pan CY, Gao Y, Lindgärde F, Broom I, Takeda H, Oana F, Matsuzawa A, Hashizume H, Akahane S, Howlett HC, Cornes M, Lund SS, Poulsen G, Frandsen M, Pedersen O, Pankiv VI, Yngen M, Hjemdahl P, Wallén NH, Florow D, Leyck Dieken MG, Kitahara Y, Mine T, Konya H, Hamaguchi T, Satani K, Umehara A, Ishikawa T, Kohri K, Hasegawa Y, Suehiro A, Kakishita E, Namba M, Wang FN, Liao ZH, Yao B, Li YB, Hu GL, Belcher G, Mariz S, Tan MH, Moules I, Pfützner AH, Butzer R, Langenfeld M, Köder C, Cooper M, Majali KA, Adiseshiah M, Betteridge J, Pratipanawatr T, Chotmongkol R, Kanhasura S, Pratipanawatr W, Miyazaki Y, Matsuda M, DeFronzo RA, Nagasawa T, Kuroda J, Dey D, Chovatia M, Nag A, Pandey B, Nag B, Thomas L, Krauth M, Allgauer S, Besenfelder U, Dennenmoser J, Moon CK, Chae SH, Kim MH, Jo YY, Shin JS, Ahn SK, Lee HW, Lee SJ, Panadero Moya A, Rodriguez E, Gonzalo A, Sánchez-Vilar O, Lara JI, Rovira A, Otto C, Otto B, Göke B, Parhofer KG, Juurinen L, Tiikkainen M, Graner M, Bajaj M, Suraamornkul S, Ucak S, Kurklu A, Argon D, Canbek E, Altuntas Y, Schöfl C, Franzen C, Gregg RE, Swaminathan A, Frost C, Nepal S, Raymond R, Mosqueda-Garcia R, Johns D, Gilmore K, Perriello G, Pampanelli S, Di Pietro C, Rinaldi T, Brunetti P, Oshinyemi K, Garcia S, Curtis P, Zambanini A, Home PD, Pocock S, Dargie H, Komajda M, Jones NP, RECORD Study Group, Münscher C, Potthoff F, Golbach U, Weidenhammer J, Kusterer K, Lundershausen R, O'Neill MC, Goldstein BJ, Wooddell MJ, Strow LJ, Waterhouse BR, Cobitz AR, Wyne KL, Porter LE, Weston WM, Chen T, James RE, Kravitz BG, Pinkowski D, Ruxer J, Mozdzan M, Siejka A, Kaiser M, Häuser C, Jacober SJ, Zagar AJ, Althouse SK, Pinaire JA, Becker RH, Frick AD, Rave K, Moses R, Ways K, Krones R, Basir S, Klein C, Sawicki PT, Rotella CM, Pala L, Dicembrini I, Mannucci E, Annuzzi G, De Natale C, Bozzetto L, Patti L, Cipriano P, Campaigne B, Malone JK, Bai S, Reviriego J, Augendre-Ferrante B, Schreiber SA, Schneider K, Schweitzer MA, Fach EM, Busch K, Karimi Anderesi Z, HOE901/4009 Study Group, Dunseath GJ, Şengül AM, Haupt A, Eckert H, Schweitzer MA, Peiker J, Fritsche A, Janka HU, Plewe G, Kliebe-Frisch C, Maxeiner S, Teng L, Chan C, Ernest CS, Skrivanek Z, Brodows RG, Soon D, Pan CY, Chung KD, Rußmann A, Ryysy L, Hänninen J, Hulme S, Kauppinen-Mäkelin R, Lahdenperä S, Lehtonen R, Levanen H, Nikkiä K, Tulokas T, Virtamo H, Vahatalo M, Fulcher GR, Lavalle-Gonzalez F, Soon DK, de la Pena A, Lim M, Scholtz HE, Derezinski T, Gerber RA, Hauber AB, Bolinder B, Johnson FR, Boehm BO, Keiding J, Home P, Raastam J, Møller MK, Parkner T, Chen JW, Jørgensen C, Smedegaard J, Christiansen JS, McDougall A, Fitch M, Nelson G, Mueller UA, Saemann A, Ishii H, Iburi T, Furuya M, Yamagami K, Sekine O, Yamashiro S, Ishibashi R, Tsujii S, Sauriol L, Lescrauwaet B, Heckmann B, Helbig C, Franke I, Schiel R, Oguzhan B, Gursoy N, Turkish Diabetes Centers Study Group, Gutiérrez E, García P, Rokeya B, Hossain ME, Ali L, Ivanova OV, Gorbenko NI, Gladkich AI, Leshchenko ZA, Gorbenko N, Ivanova O, Gorbenko K, Blase E, Taylor K, Nguyen T, Su G, Gao HY, Carr E, Wintle M, Fineman M, Calara F, Han J, Aisporna M, Zabala E, Fehse F, Trautmann ME, Halseth AE, Nauck MA, Kendall DM, Riddle MC, Zhuang D, Kim DD, Fineman MS, Baron AD, Buse J, Henry R, Ratner R, Linnebjerg H, Kothare P, de la Peña A, Ernest C 2nd, Atkins M, Trautmann M, Bjerre Knudsen L, Voss PV, Nauck M, Hompesch M, Filipczak R, Le TT, Nielsen L, Zdravkovic M, Gumprecht J, Deacon CF, Plamboeck A, Guivarch PH, Dreyfus JF, Mathi S, Castaigne JP, Drucker DJ, Kruger D, Burrell T, Gloster M, Crean J, Herrmann K, Maggs D, Kolterman O, Kovatchev B, Cox DJ, McCall A, Whitehouse F, Kovatchev BP, Chapman I, Parker B, Doran S, Feinle-Bisset C, Wishart J, Lush C, Mcintyre S, Deckhut D, Horowitz M, El-Ouaghlidi A, Rehring E, Holmes D, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Foley JE, Narayanan S, Thomas A, Shah D, Gopalan B, Vakkalanka S, Arch J, Ryskjær J, Krarup T, Madsbad S, Vilsbøll T, Ciani S, Bardini G, Pezzatini A, Cappadona A, Bödvarsdóttir TB, Joergensen MS, Jensen-Holm HB, Kristensen L, Kanstrup AB, McKillop AM, Duffy N, Lindsay JR, Bell PM, Hansen BS, Gronemann S, Wilken M, Herman GA, Zhao PL, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Hilliard D, Tanen M, De Smet M, Van Dyck K, Tanaka W, Gottesdiener KM, Wagner JA, Hoffmann T, V Hörsten S, Demuth HU, Paule SG, Myers MA, Nikolovski B, Fujiwara H, Hosokawa M, Fukuda K, Nishi Y, Fujita Y, Yamada K, Ueda N, Jones-Leone AR, Yu T, Barilla D, He YL, Ho Y, Foley J, Makrilakis K, Panagiotakos DB, Dimosthenopoulos C, Ioannidis I, Chrysohoou C, Pitsavos C, Kuo SW, Levendal RA, Frost CL, Poonsatha S, Jones G, Fahey R, Collier G, Hoa NK, Norberg Å, Liepinsh E, Phan DV, Thuan ND, Jörnvall H, Sillard R, Östenson CG, Tessari P, Kiwanuka E, Cristini M, Zaramella M, Enslen M, Garcia-Rodenas C, Yazawa M, Imai Y, Ohmura E, Tsuchida A, Matsuda A, Hosaka D, Horie H, Ichita M, Hisano Y, Woodhead S, Xu W, Chen XH, Cavalot FL, Bonomo K, Perna P, Bacillo E, Salacone P, Gallo M, Gaia E, Vinik AI, Yu D, Heise MA, Freed MI, Aguilera E, Pellitero S, Näf S, Bendtzen K, Nicoletti F, Hahn JU, Bochnig S, Koenig H, Sporleder B, Maisonneuve P, Lowenfels AB, Kerner W, Lankisch PG, Thai AC, Mohan V, Khalid BA, Yeo JP, ASDIAB Study Group, Gasiorowska A, Talar-Wojnarowska R, Malecka-Panas E, Schindler K, Rieger A, Gmeinhart B, Schlembacher K, Merz P, Ludvik B, Müller N, Rodriguez FU, Aas AM, Seljeflot I, Huang C, Biswas N, Hashimoto N, Kamatani Y, Suzuki Y, Yagui K, Saito Y, Iwai R, Takahashi H, Yoshida S, Skowronski M, Zozulinska D, Juszczyk J, Wierusz-Wysocka B, Böhles HJ, Peterkova VA, Kuraeva TL, Scherbacheva LN, Andrianova EA, Maximova VP, Titovich EV, Danne T, Bittner C, Hanaire-Broutin H, Schumicki DM, Souhami E, Morrison G, Purewal TS, Weston PJ, Šmahelová A, Rušavý Z, Kožnarová R, Loyková V, Bělobrádková J, DeVries JH, Retnakaran R, Hochman J, Melki V, Zinman B, Corbi S, Costanza F, Fioriti E, Cappa M, Jaroň M, Martínek V, Piechatzek R, Klaff L, Prager R, Robinson A, Penfornis A, Garg SK, Thomas R, Selam JL, Sola-Gazagnes A, Vitacolonna E, Canonico V, Fabietti P, Iorio M, Orsini Federici M, Timi A, Massi Benedetti M, Sarti E, Ashwell SG, Gebbie J, Siebenhofer A, Plank J, Berghold A, Horvath K, Mrak P, Jeitler KJ, Pieber TR, Heller S, Gottlieb P, Paul J, Chase P, Menditto L, Antuña R, Grimaldi A, Brun JM, Vialettes B, Halimi S, Dubroca I, Blayo A, Gómez-Peralta F, Santos-Mazo E, Payeras-Más F, Abreu-Padín C, Santos-Palacios S, Salvador-Rodríguez J, Burge MR, Schroeder E, Witthaus E, Johnston P, Bradley C, Kudva YC, Jenkins G, Pons G, Quandt L, Gebel J, Vogelsang D, Smith S, Isley W, Russell-Jones D, Maier C, Mustapic D, Schuster E, Luger A, Eher R, Koznarova R, Rubesova I, Pelikanova T, Skibova J, Sanz FJ, Ampudia-Blasco FJ, Gabaldon J, Catala M, Carmena R, Heinemann L, Kronshage B, Ward K, Sass D, Essenpreis M, Voelkel D, Lodwig V, Nguyen M, Mondok A, Friedrich C, Caduff A, Totonelli A, Longhitano S, Agrò F, Edelman SV, Morrison Z, Velazquez F, Howard S, Banks R, Berger B, Burian P, Nilsson KA, Karlén M, Rylander E, Blonde L, Freemantle N, Ross SA, Duhot D, Eggertsen R, Hobbs FD, Martinez L, Stridde E, Skyler JS, Tusek C, Stephan JA, Krasner A, Landschulz WH, Sha S, Bott S, Bergenstal RM, Damgé C, Ubrich N, Kaltenbacher MC, Maincent P, Wutte A, Bock G, Balent B, Midtgaard A, Rønn BB, Pieber T, Edgerton DS, Cherrington AD, Neal DW, Scott M, Glass D, Bowen LE, Wilson W, Hobbs CH, Leach C, Sivakumaran S, Strack TR, De Meyts P, Aladdin H, Palsgaard J, Theede AM, Sajid W, Hinrichsen J, Klaproth B, Lademann J, Østergaard J, Andersen AS, Boss AH, Cheatham WW, Pfuetzner A, Larbig M, Forst S, Abdollahnia R, Grenningloh M, Leatherdale B, Bartley E, Schwartz SL, Buchea O, Shin J, Hoss U, Shah R, Endo T, Hata S, Yamazaki H, Hernandez Campos S, Busciantella Ricci N, Kaufman F, Halvorson M, Carpenter S, Cooper K, Mueller J, van Wasen H, Brumberg J, Rduch K, Mertens S, Reeß F, Renz H, Maran A, Sparacino G, Pavanini A, Corazza S, Crepaldi M, Poscia A, Acosta D, Salcedo D, Delgado E, Novoa J, Hawkins F, Parramón M, Mesa J, Parhimovich RM, Darko DA, Odusanya PO, Pullen F, Hopkins DF, Mukherjee S, Child DF, Redkin YA, Dreval AA, Bogomolov VV, Dreval AV, Östgren CJ, Grodzinsky E, Lindström K, Borgquist L, Fegan G, Hamliton P, McCrimmon RJ, Evans ML, Fan X, Ding Y, Sherwin R, Boomsma F, Pramming S, Fischer BM, Soydan N, Eckhard M, Saar P, Kreuder J, Linn T, Holstein A, Plaschke A, Ptak M, Egberts EH, El-Din J, Kirchheiner J, Hoashi S, Khamis A, Kilbane MT, Cannon DE, Gribben AP, Firth RG, Kinsley BT, Cranston IC, De Galan BE, De Mol P, Wennekes L, Due-Andersen R, Lundkvist J, Jönsson L, Mukhopadhyay B, Deans KA, Kesson CM, Jendrike N, Buck H, Abicht A, Haug C, Freckmann G, Warren RE, Sommerfield AJ, Allen KV, Deary IJ, Frier BM, Høi-Hansen T, Wu A, Holtman V, Plaschke AJ, Tenberken O, Maurer HH, Al-Zakwani I, Bullano MF, Baron JJ, Willey VJ, Nattrass M, Kurtzhals P, Colding-Jorgensen M, Riddle M, Massi-Benedetti M, Murray F, Lin Z, Kølendorf K, Prasek M, Philotheou A, Javashvili L, Virsaladze D, Kajaia N, Raposo JF, Pratas S, Fernandes C, Valadas C, Duarte R, Gardete-Correia L, Boavida J, Locatelli M, Patera IP, Bottazzo GF, Hadjidakis D, Mylonakis A, Raptis A, Papaefstathiou A, Hedman CA, Frystyk J, Fridell K, Jönsson A, Lindström T, Saito M, Eto M, Kaku K, Stotzka M, Stein G, Prince MJ, Kulzer B, Scholze A, Hermanns N, Kubiak T, Starostina EG, Shavrikova EP, Furuhashi N, Hirose T, Kuroda M, Kimura M, Ishizawa M, Sarui H, Takeda N, Furuta T, Drewelow S, Lindloh C, Paddison CA, Faimalie M, Flett RA, Micheletti S, Perelli Cippo P, Mantovani LG, Su M, Trento M, Bajardi M, Passera P, Miselli V, Tomalino M, Borgo E, Cavallo F, Porta M, Miclea S, Bogatean M, Hancu ND, Leppert K, Muller UA, Rittmeier H, Hancu N, McHorney C, Myers J, Reinecker H, Meier JJ, Gallwitz B, Askenas M, Vollmer K, Schmidt WE, Kyrou I, Souvatzoglou E, Cseh K, Baranyi E, Kaszas E, Szocs A, Melczer Z, Sikter M, Szenthe P, Palik E, Hajos P, Pogatsa G, Winkler G, Pardo IC, Barros-Filho AA, Jahan S, Huq F, Biswas KB, Chowdhury TA, Khan AR, Ritterath C, Talai Rad N, Siegmund T, Heinze T, Henrich W, Siebert G, Dudenhausen J, Buhling K, Kautzky-Willer A, Mustafa S, Winzer C, Vukovich T, Shaat N, Ekelund M, Lernmark Å, Ivarsson S, Zmudzinska M, Bronisz A, Pufal M, Junik R, Beran DH, Toledano Y, Giveon S, Kahan E, Aycheh S, Guttman N, Jaffe A, Alberti H, Boudriga N, Nabli M, Jaiveer S, Jaiveer PK, Lee JD, Shaikh S, Gopinath A, Morrissey JR, Patel V, Lenz M, Dvoynishnikova OM, Mayorov AY, Galstyan GR, Antsiferov MB, Dedov II, Rybarczyk M, Scalone L, Palmer AJ, Morgutti M, Valentine WJ, Renaudin C, Roze S, Morsanutto A, Berto P, Lopatriello S, Voinovich D, Gelisio R, Brändie M, Russ W, Greiner RA, Rodríguez J, Rubio Terrés C, de Pablos P, Smith IC, Wittrup-Jensen K, Morgan CL, Tsutskiridze L, Haag B, DelBuono B, Silva C, Fox A, Padilla V, Naraine K, Cypryk K, Szymczak W, Szosland K, Sobczak M, Zawodniak-Szalapska M, Lewinski A, Schvarcz E, Lindqvist A, Stenninger E, Östlund I, Åman J, Lapolla A, Dalfrà M, Di Benedetto A, Dolci M, Franzetti I, Masotti M, Napoli A, Salietti G, Santini C, Tortul C, Di Cianni G, Popow C, Waldhör T, Horn W, Biermann E, Rihl J, Riedl M, Kastner P, Kollmann A, Pusch W, Schreier G, Hearnshaw HM, Lowe P, Griffiths FE, Stapperfend MC, Baehring TU, Cosson E, Benchimol M, Carbillon L, Pariès J, Lormeau B, Valensi P, Pharisien I, Tourel E, Uzan M, Attali JR, Zabarovskaya ZV, Mulyarchik OV, Shepelkevich AP, Barsukov AN, Guseva TK, Begum K, Haque L, Bokor A, Rigó J, Garamvölgyi Z, Pusztai P, Somogyi A, Hanson U, Nyström L, Blohmó G, Ekbom-Schnell A, Östman J, Persson B, Parretti E, Cioni R, Marzari C, Masin M, Scarselli G, Mello G, Seghieri G, De Bellis A, Anichini R, Alviggi L, Franconi F, Breschi CM, Dworacka M, Wender-Ożegowska E, Winiarska H, Macugowska M, Zawiejska A, Bobkiewicz-Kozłowska T, Pietryga M, Brązert J, Bousboulas S, Politakis P, Papadimitriou P, Lyu R, Yin DD, Green A, Kristensen JK, Rodríguez-Saldaña J, Clark CM Jr, Morales de Teresa M, Escorza-Domínguez AB, Ortiz-Gress AA, Monroy-Mayorga A, Mejía-Pedraza BJ, Seeliger S, Kaiser J, Müller E, Maxion-Bergemann S, Bergemann R, Goertz A, Shearer A, Bagust A, Schoeffski O, Mayorov A, Shestakova M, Antsiferov M, Balabolkin M, Chugunova L, Shamkhalova M, Zaytseva N, Naumenkova I, Brevnova N, Dedov I, Tsibina L, Rosak C, Petzoldt R, Stammer H, Dehmel B, Seidel DK, Roth W, Fennenkötter U, Gottschall V, Kanatsuka A, Lauenborg J, Mathiesen E, Jörgensen T, Hornnes P, Wagner OF, Zajdenverg L, Halfoun VL, Oliveira JE, Lencioni C, Volpe L, Chatzianagnostou K, Cuccuru I, Ghio A, Pardini E, Salvadorini M, Saltiki A, Korakovouni A, Stavrianos H, Zapanti E, Antsaklis A, Pithova P, Sporna M, Bustani R, Todd DM, Lawrence I, Guerrero R, Vázquez M, Amaya M, Dios E, Quijada D, García-Hernández N, Astorga R, Gandhi RA, Jayawarna C, Fernando DJ, Hill RP, Lloyd-Mostyn RH, Thomson GA, Rewers A, Bothner J, Klingensmith G, Sysoyeva O, Karlovich N, Rankins D, Wellard M, Werther G, Northam E, Kordonouri O, Haberland H, Hauschild M, Kapellen T, Kraft V, Wiemann D, Lange K, Witte DR, Fuller JH, EURODIAB PCS Group, Laude D, Dabire H, Hadj Brahim F, Papanas N, Papatheodorou K, Christakidis D, Papazoglou D, Giassakis G, Piperidou H, Monastiriotis H, Maltezos E, Barrett C, Serghides H, Tindali H, Kelly F, Chiheb S, Chen Q, Brahimi M, Cynober L, Delaporte C, Scionti L, Conti M, Vermigli C, Galimberti G, Cazzetta G, Bosi E, Sugimoto K, Shoji M, Yasujima M, Suda T, Yagihashi S, Mabley J, Zsengeller Z, Charniauskaya T, Abatan OI, Kimura I, Tsuneki H, Hara S, Sasaki K, Nangle MR, Gibson TM, Yorek MA, Hirooka H, Stevens MJ, Tarhzaoui K, Cohen-Boulakia F, Smith G, Lestrade R, Behar A, Komori H, Oi K, Takahashi D, Kunitou T, Moroi M, Philips JC, Marchand M, Geronooz I, Scheen AJ, Gambardella S, Ciampittiello G, Bracaglia D, Cicconetti E, Gigli F, Verri C, Baroni A, Frontoni S, Szabó M, Germán M, Farkas L, Szentendrei D, Maiello MR, Mandica S, Morganti R, Menzinger G, Bernardi L, Aso Y, Wakabayashi S, Takebayashi K, Takemura Y, Inukai T, Kalter-Leibovici O, Lifshitz A, Yerushalmy Y, Stern E, Ogawa K, Nanjo K, Kawamori R, Katayama S, Shirai M, Fonseca V, Seftel A, Denne J, Fredlund P, Buvat J, Schmitt H, van Ahlen H, Varanese L, Lips J, Hoekstra JB, Banga JD, Legros JJ, Lufuma M, Bouter KP, Fan LF, Lu JM, Zheng YG, Zhang XQ, Spruce MC, Jones C, Coppini DV, Lavery LA, Holtz-Neiderer K, Mohler MJ, Wendel CS, Nixon BP, Jurado J, Bataller F, Dorca A, Garcia F, Brossa N, Barnera T, Pou Torelló JM, Bregovski VB, Karpova IA, Hedetoft C, Rasmussen A, Fabrin J, Driver VR, Thoms TL, Jeffcoate WJ, Monaghan J, Game FL, Dalla Noce S, Cimmino M, Caruso S, Manes C, Mikoudi K, Sossidou E, Pigas G, Karagianni D, Skoutas D, Fotiadis S, Pruna S, Eroshkin IA, Vasiljev YG, Udovichenko OV, Udovichenko AE, Bondarenko ON, Dang CN, Prasad YD, Anwar R, Thomas G, Malik R, Lobmann R, Motzkau M, Pittasch D, Lehnert H, Piaggesi A, Marsocci A, Fanara MG, Rizzo L, Palumbo F, Campi F, Tedeschi A, Scatena A, Goretti C, Baicchi U, Chipchase S, Treece K, Pound N, Hill NR, Cyganek K, Mirkiewicz-Sieradzka B, Malecki M, Wolkow P, Skupien J, Naskalska A, Sieradzki J, Tapp RJ, Tonkin AM, Harper A, McCarty DJ, Söderberg S, Taylor HR, Chitson P, Alberti GK, Sheetz MJ, Aiello LP, Davis MD, Milton RC, Arora V, Hu K, Girach A, Vignati L, Tyrberg M, Melander A, Lindblad U, Giannarelli R, Coppelli A, Sartini M, Aragona M, Fletcher EL, Ninkovic S, Foster LE, Jones D, De Gooyer T, Stitt A, Vingrys AJ, Wilkinson-Berka JL, Lewandowska AB, Randeva HS, Komorowski J, Lewandowski KC, Jurowski P, Sankar S, Gos R, Kowluru RA, Odenbach S, Shinn S, Oh YS, Kim J, Agardh CD, Hultberg B, Agardh E, Segura RM, Fonollosa A, Berrone E, Beltramo E, Solimine C, Ubertalli A, Islam N, Esteve E, Fernandez M, Recas I, Mauri S, Biarnes F, Junca E, Fernádez-Real J, Rössner S, Stenlof K, Levy B, Perry B, Fitchet M, Chrysos G, Kamaratos A, Lepeniotis G, Kokkoris S, Varytimiadis K, Stasini F, Mikros S, Gianneli D, Tryfinopoulou K, Melidonis A, Nikolopoulou C, Harley K, Ryder R, De P, VanNieuwenhoven FA, Rossing K, Oliver N, Goldschmeding R, Jacobsen PK, Tan F, Liew S, Mukherjee JJ, Lim P, Fröjdö S, Sjölind L, Parkkonen M, Mäkinen V, Tikellis C, FinnDiane Study Group, Nieuwenhoven FA, MacIsaac RJ, Tsalamandris C, McNeil KJ, Panaiotopoulos S, Smith TJ, Ho M, Matthews PG, Jerums G, Hut H, van den Meiracker AH, Nakhjavani M, Behjati J, Esteghamati A, Esfahanian F, Aghamohamadzadeh N, Abbasi M, Kohnert KD, Zander E, Krabbe S, Stehouwer CD, Schalkwijk CG, Saraheimo MT, Krarup Hansen T, Teppo AM, Ebeling P, Hansen BV, Abdella NA, Mojiminiyi OA, Al Dahi WA, Al Mohammedi H, Al Jebely S, Neugebauer-Baba S, Baba T, Ohashi H, Nakajima S, Hesselmann C, Watanabe T, Nargis M, Zaid RB, Voronko OE, Shestakova MV, Shamkhalova MS, Tchugunova LA, Vikulova OK, Nosikov VV, Liu L, Zheng T, Li M, Zhang R, Xiang K, Hadjadj S, Jeunemaitre X, Vervoort G, Veldman B, Berden J, Wetzels J, Singh BM, Holland MR, Baskar V, Oh J, Seo J, Choi K, Baik S, Choi D, Kim N, Matsumoto S, Suetsugu M, Matsutomo R, Pisarczyk-Wiza D, Banaszak A, Wysocki H, Usui H, Shikata K, Okada S, Ogawa D, Yozai K, Kido Y, Nagase R, Ohga S, Tone A, Sasaki M, Wada J, Unno Y, Horiuchi S, McLennan SV, Kamarinos M, Kelly D, Waltham M, Dy V, Yue D, Langham R, Gilbert R, Zdychova J, Komers R, Cresci B, Giannini S, Manuelli C, Giunti S, Pinach S, Ianni Palarchio A, Arnaldi L, Vittone F, Camussi G, Cavallo Perin P, Gruden G, Marshall SM, Jones SE, White KE, Brizzi M, Dentelli P, Rosso A, Calvi C, Gambino R, Cassader M, Salvidio G, Deferrari G, Pegoraro L, Pagano G, Cavallo-Perin P, Oates R, Ellery C, Beebe D, Coutcher J, Qian YZ, Lowe V, Appleton T, Raunig D, O'Neil S, Mylari B, Amazonas RB, Fujita A, Doi A, Matsuno S, Okamoto K, Matsumoto E, Furuta H, Nishi M, Tsuno T, Taniguchi H, Bessho H, Wasén E, Isoaho R, Mattila K, Vahlberg T, Kivelä SL, Irjala K, Rigalleau V, Lasseur C, Perlemoine C, Barthes N, Raffaitin C, Chauveau P, Combe C, Baillet-Blanco L, Beauvieux MC, Gin H, Heinrich S, Steiner T, Ott U, Holdass H, Fellström B, Jardine A, Staffler B, Logan JO, Gimpelewicz C, Stanciu CC, Pena CM, Serafinceanu CC, González-Posada JM, Hernández D, Pérez-Tamajó L, Ló AJ, Herná Alarcó M, Meneses M, Barsotti M, Rizzo G, Schmauss S, Havrdova T, Saudek F, Boucek P, Adamec M, Invitti C, Gilardini L, Parati G, Mazzilli G, Pontiggia B, Sartorio A, Lutgers HL, Groenier KH, Zasadzinska G, Saryusz-Wolska M, Temelkova-Kurktschiev TS, Kurktschiev DP, Majdrakova I, Varbanova T, Todorova B, Bajo-Martinez A, Bernal E, Sanchez O, Ugalde-Canitrot A, Sanchez-Largo E, Coca-Robinot D, Fabregate R, Calbacho M, Marquez J, Saban-Ruiz J, Penesova A, Cizmarova E, Blazicek P, de Jongh RT, Serné EH, Ijzerman RG, de Vries G, Stehouwer CD, Poulsen PL, Andersen NH, Knudsen ST, Helleberg K, Mogensen CE, Waluś M, Idzior-Waluś B, Sztefko K, Cieślik G, Fedak D, Wozniakiewicz E, Lin SD, Guo MY, Lin CJ, Liu XC, Francisco MJ, Rodriguez-Rosas H, Peiró-Martinez I, Macías-Batista A, Harte AL, Rodriguez-Cuenca S, Valsamakis G, Chetty R, Anderson LA, Roca P, Matyka K, LaSalle J, Hershon K, Berman L, Gibson E, Gillen D, Maroni J, Simmons D, Hiukka A, Forder P, Leinonen E, Hilden H, Fruchart J, Fruchart JC, Keech A, Farnier M, Freeman M, Macdonell G, Perevozskaya I, Mitchel Y, Gumbiner B, Didangelos TP, Athyros VG, Mikhailidis DP, Papageorgiou AA, Bouloukos VI, Pehlivanidis AN, Symeonidis AN, Elisaf M, McKenney J, Insull W Jr, Lewin A, Maccubbin D, Lee M, Kush D, Schuster H, Barter PJ, Stender S, Cheung RC, Bonnet J, Morrell JM, Watkins C, Kallend D, Stalenhoef AF, Ballantyne CM, Murin J, Tonstad S, Rose H, Wilpshaar W, Jenkins A, Karschimkus C, Dragicevic G, Rowley K, Wolthers T, Best JD, Voet B, Murdoch SJ, Marcovina SM, Chen HC, Brunzell JD, Caparevic ZV, Kostic ND, Ilic SM, Sartore G, Piarulli F, Cantaro S, Reitano R, Fiore C, Marin R, Bassan S, Manzato E, Fedele D, Solini A, Santini E, Thornalley PJ, Babaei-Jadidi R, Karachalias N, Kupich C, Ahmed N, Fowler AE, Baker AR, Starczynski J, O'Hare P, Szepietowska B, Szelachowska M, Puch U, Glebocka A, Quinn DW, da Silva NF, McTernan CL, Bonser RS, McTernan P, Idzior-Walus B, Woźniakiewicz E, Dimitriou K, Apostolou O, Kontela E, Devangelio E, Gould EM, Serri O, Roussin A, Buithieu J, Mamputu JC, Renier G, Giordanetti S, De Amici E, Poggi G, Turpini C, Fratino P, Garzaniti A, Yin D, Banu I, Paries J, Roman G, Negrean M, Bala CG, Nita C, Kistorp C, Gustafsson F, Chong A, Lip G, Galatius S, Shearer AT, Ari N, Sahilli M, Ceylan-Isık A, Ozansoy G, Karasu-Yilmaz C, Matteucci E, Rosada J, Pallini M, Evangelista I, Cassetti G, Giusti C, Giampietro O, Capaldo B, Galderisi M, Cicala S, Turco A, Imbroinise A, Nosso G, D'Errico A, de Divitiis O, Klimontov VV, Korolyova EA, Jeltova LI, Bondar IA, Tarkun I, Arslan B, Canturk Z, Tarkun P, Agacdiken A, Komsuoglu B, Méneveau N, Pierre-Justin E, Alsayed M, Sabbah R, Paulin S, Marcu S, Tauveron I, Zimmermann C, Schiele F, Seronde ME, Vautrin P, Lusson JR, Thieblot P, Bernard Y, Mistry A, Pye MP, Peovska I, Maksimovic Pavlovic J, Vavlukis M, Pop Gorceva D, Bosevski M, Scognamiglio R, Negut C, de Kreutzenberg S, Madonna R, De Caterina R, Willerson JT, Geng YJ, Vahsen S, Ledwig D, Ramrath S, Frantz S, Schmidt I, Calvillo L, Dienesch C, Elbing I, Bischoff H, Ertl G, Bauersachs J, Davydov AL, Mkrtum'yan AM, Baranova LY, Ikeda Y, Suehiro T, Osaki F, Ota K, Arii K, Kumon Y, Hashimoto K, Doney AS, Fischer B, Morris AD, Palmer CN, Ahn YM, Lee BC, Kim SI, Byun SH, Ahn SY, Doo HK, Pagnin E, Calo LA, Fadini G, Kubaszek A, Chai S, Chai Q, Rasmussen L, Ledet T, Wogensen L, Lengyel C, Varró A, Virág L, Magyar J, Bíró T, Jost N, Skoumal R, Nánási P, Tóth M, Horkay F, Papp JG, Zacharopoulou O, Athanaselis S, Tsokos N, Doupis J, Psallas M, Cokkinos D, Pavlatos S, Liatis S, Akhobadze T, Dzneladze L, Samarguliani I, Taskiran M, Rasmussen V, Rasmussen B, Jensen GB, Fisher AA, Petrovsky N, Davis MW, Srikusalanukul W, Budge MM, Trifunovic-Zamaklar DD, Zivkovic M, Jelic V, Vukomanovic G, Ristic AD, Seferovic PM, Costa JV, Duarte S, Manley SE, Sailesh S, Venkataraman A, Haider Y, Groza I, Oprean M, Ardelean A, Morosanu A, Darkow T, Vanderplas A, Mamas MA, McElduff P, Burns J, Edwards R, Fitchet A, Young RJ, Gibson JM, New JP, Lichiardopol R, Niculescu N, Totora A, Pencea C, Tomescu I, Cinteza M, Manicardi V, Coscelli C, Navazio A, Catellani E, Michelini M, Dall'Asta D, Guberti A, Piazza A, Gasparini E, Pantaleoni M, Guiducci U, Manari A, Sejil S, Janand-Delenne B, Avierinos JF, Habib G, Labastie N, Vague P, Lassmann-Vague V, Luźniak P, Tatoń J, Wojciechowska Luźniak A, Zairis M, Lyras A, Patsourakos N, Tsirimbis V, Foussas S, Lupón J, Urrutia A, Herreros J, González B, Coll R, Altimir S, Prats M, Valle V, Abreu-Padí C, Rábago G, Ivanova LA, Brasacchio D, Calkin A, Jandeleit-Dahm KA, Harno E, Keenan AK, Li HL, Yu YR, Lu ZM, Zhang XE, Ke L, Liu H, Zhang XX, Jeong IK, Chae MK, Choi MH, Yoo HJ, Kim CD, Yun MR, Na MA, Kang YH, Kong ON, Son SM, Kim IJ, Kim YK, Tanaka N, Hosoi M, Matsuyama Y, Fukumoto M, Yamakita T, Yoshioka K, Ishii T, Sato T, Fujii S, Aoki T, Shibata T, Mizutani N, Suzuki JY, Fowelin JH, Samuelsson P, Brandrup-Wogsen G, Okumura K, Tokmakova AY, Staroverova DN, Antcieferov MB, Shutichina IV, Kuntchevich GI, Vriesendorp TM, Morélis QJ, Legemate DA, Schaper F, Mainas EI, Gkioulmpasanis I, Panagiotou I, Vassilikos G, Skorda L, Sidira M, Christoforidou M, Alaveras A, Artikis V, Evdemon E, Lechleitner M, Koch T, Ebenbichler C, Sturm W, Moretti L, Moruzzo D, Boldrini E, Pandolfo C, Kameyama M, Iwasa R, Cho MH, Nam JY, Kim CS, Kim DM, Ahn CW, Cha BS, Lim SK, Kim KR, Lee HC, Huh KB, Kaplar M, Paragh G, Erdei A, Csongradi E, Garai I, Varga J, Galuska L, Udvardy M, Higa M, Kaneko Y, Hiroi N, Koziarska D, Nowacki P, Majkowska L, Luzniak P, Wojciechowska-Luźniak A, Tushuizen ME, Nieuwland R, Snoeck DP, Sturk A, Diamant M, Aguiar LG, Bahia L, Villela N, Laflor C, Conde C, Bottino D, Dorigo D, Bouskela E, Pu S, Yu HL, Luo ZT, Lam KS, Dan Q, Xu A, Shen J, Cheng K, Xu JY, Thamer C, Stefan N, Haap M, Heller E, Tschritter O, de Prado A, Ortiz A, Ybarra J, Gich I, Pou JM, Ehren M, Meyer MF, Roggenland D, Reinsen B, Klein HH, Rittig K, Stock J, Kocher B, Balletshofer B, Lee J, Shon HS, Chung DS, Nakatani Y, Matsuhisa M, Kaneto H, Hatazaki M, Yoshiuchi K, Katakami N, Kawamori D, Ohtoshi K, Sakamoto K, Matsuoka TA, Ozawa K, Ogawa S, Hori M, Yamasaki Y, Zitouni K, Harry D, Nourooz-Zadeh J, Betteridge JD, Earle KA, Rasmussen LM, Olesen P, Franco L, Corvaja C, Semplicini A, Ceylan-Işık A, Arı N, Rösen P, Lee IK, Kim MJ, Park KG, Jung ED, Shin DW, Jo SR, Obuobie K, Prakash PK, Hanna FW, Evans M, Lazarus J, Varadhan L, Gurushankar J, James D, Sheikh S, Gaede P, Li H, Zou D, Lee SJ, Choi MG, Kim DS, Kim TW, Vilarrasa N, Perez-Maraver M, Mena E, Perez D, Setti G, Buckingham R, Urbančič V, Stefanovska A, Bernjak A, Ažman-Juvan K, Kocijančič A, Glowania A, Filters TS, Fosmark DS, Torjesen PA, Kilhovd B, Berg TJ, Sandvik L, Hanssen KF, Mentink CJ, Kilhovd BK, Kuchmerovska TM, Shymanskyy IO, Donchenko GV, Stepanenko SP, Klimenko AP, Park J, Maingrette F, Deng HC, Lindenmair A, Waldhäusl WK, Freudenthaler A, Baumgartner-Parzer SM, Nizheradze K, Khoruzhenko A, Tronko N, Sheu WH, Ou HC, Shen HM, Lin TM, Wu HS, Yang CH, Mogylnytska L, Mankovsky B, Schmoelzer I, Davies JI, Band M, Morris A, Struthers AD, Prázný M, Škrha J, Kasalová Z, Neelotpol S, Jahan P, Kauschke SG, Harrop CA, Schäfer A, Widder J, Eigenthaler M, Walter U, Uchimura I, Ikebukuro M, Kaibara M, Hirata M, Helal R, Pervin F, Khan AK, Yang X, Jansson PA, Nagaev I, Jack MM, Carvalho E, Sunnerhagen KS, Cam MC, Cushman SW, Smith U, Creely SJ, Farmer J, Creely S, Gustafson B, Kusminski CM, Krusinova E, Wohl P, Klementova M, Lanska V, McDougall C, Thomas SJ, Kelly I, Abbas ZG, Lutale JK, Archibald LK, Karunajeewa H, Stingemore N, Stuccio G, McGechie D, Muller LM, Hak E, Goudzwaard WL, Montorsi F, Homering M, Sprenger K, Goldstein I, Asnaghi V, Ferrari G, Rastaldi M, Gabellini D, Dell'Antonio G, Maestroni A, Ruggieri D, Luzi L, Piemonti L, Zerbini G, Anafaroglu I, Tutuncu NB, Sultana M, Siddiqua N, Iwasaki T, Nakajima A, Yoneda M, Mukasa K, Tanaka S, Sekihara H: 40&lt;sup&gt;th&lt;/sup&gt; EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004. Diabetologia; 2004 Aug;47(Suppl 1):A1-A464
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 40<sup>th</sup> EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004.

  • HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27770180.001).
  • [ISSN] 1432-0428
  • [Journal-full-title] Diabetologia
  • [ISO-abbreviation] Diabetologia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down

9. Gopal AK, Gooley TA, Maloney DG, Petersdorf SH, Eary JF, Rajendran JG, Bush SA, Durack LD, Golden J, Martin PJ, Matthews DC, Appelbaum FR, Bernstein ID, Press OW: High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood; 2003 Oct 1;102(7):2351-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.
  • We performed a multivariable comparison of 125 consecutive patients with follicular lymphoma (FL) treated at our centers with either high-dose radioimmunotherapy (HD-RIT) using 131I-anti-CD20 (n = 27) or conventional high-dose therapy (C-HDT) (n = 98) and autologous hematopoietic stem cell transplantation.
  • The groups were similar, although more patients treated with HD-RIT had an elevated pretransplantation level of lactate dehydrogenase (41% versus 20%, P =.03) and elevated international prognostic score (41% versus 19%, P =.02).
  • Patients treated with HD-RIT received individualized therapeutic doses of 131I-tositumomab (median, 19.7 GBq [531 mCi]) to deliver 17 to 31 Gy (median, 27 Gy) to critical organs.
  • Patients treated with C-HDT received total body irradiation plus chemotherapy (70%) or chemotherapy alone (30%).
  • Patients treated with HD-RIT experienced improved overall survival (OS) (unadjusted hazard ratio [HR] for death = 0.4 [95% confidence interval (95% CI), 0.2-0.9], P =.02; adjusted HR, 0.3, P =.004) and progression-free survival (PFS) (unadjusted HR =.6 [95% C.I., 0.3-1.0], P =.06; adjusted HR, 0.5, P =.03) versus patients treated with C-HDT.
  • The estimated 5-year OS and PFS were 67% and 48%, respectively, for HD-RIT and 53% and 29%, respectively, for C-HDT.
  • One hundred-day treatment-related mortality was 3.7% in the HD-RIT group and 11% in the C-HDT group.
  • The probability of secondary myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) was estimated to be.076 at 8 years in the HD-RIT group and.086 at 7 years in the C-HDT group.
  • HD-RIT may improve outcomes versus C-HDT in patients with relapsed FL.
  • [MeSH-major] Antigens, CD20 / immunology. Hematopoietic Stem Cell Transplantation. Iodine Radioisotopes / therapeutic use. Lymphoma, Follicular / radiotherapy. Lymphoma, Non-Hodgkin / radiotherapy. Radioimmunotherapy / methods
  • [MeSH-minor] Adult. Cohort Studies. Combined Modality Therapy. Disease Progression. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / radiotherapy. Survival Rate. Treatment Outcome

10. Jang IG, Yang JK, Lee HJ, Yi JY, Kim HO, Kim CW, Kim TY: Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J Am Acad Dermatol; 2000 Jun;42(6):1033-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Several clinical studies have focused on the therapeutic effects of interferon gamma (IFN-gamma) in patients with severe atopic dermatitis (AD), although the dosage of recombinant IFN-gamma (rIFN-gamma), therapeutic schedule, and the degree of clinical improvement were different among studies.
  • Although the exact mechanism of action of IFN-gamma therapy in AD is not clear, the beneficial effects of IFN-gamma have been attributed mainly to an immunomodulating effect on the expression of certain immunologic markers.
  • OBJECTIVE: Our purpose was to study the therapeutic effect of two different dosages of rIFN-gamma on AD and to investigate the change of lesional expression of infiltrating inflammatory cell markers associated with rIFN-gamma therapeutic efficacy.
  • Twenty patients were treated with 0.5 x 10(6) IU/m(2) of rIFN-gamma (low-dose [LD] group); 21 patients received 1.5 x 10(6) IU/m(2) of rIFN-gamma (high-dose [HD] group); and 10 patients received placebo.
  • The patients were injected subcutaneously 3 times a week for 12 weeks.
  • Immunohistochemical study was performed in 20 patients of the HD group in the initial visit and after completion of rIFN-gamma therapy with a panel of 14 monoclonal antibodies as markers of inflammatory cells and cytokines.
  • RESULTS: The disease severity of the 2 groups treated with rIFN-gamma was reduced significantly at the end of treatment compared with that of the placebo group (P<.05).
  • More rapid clinical improvement and more effective treatment outcome were seen in the HD group than in the LD group for the initial 6-week treatment period; however, the clinical improvement in both of the treated groups was stable and maintained after week 8 of treatment.
  • Immunohistochemical findings showed statistically significant reduction in the lesional expression of CD25 and EG2 cells that infiltrated into skin after rIFN-gamma therapy.
  • CONCLUSION: This study demonstrated that rIFN-gamma therapy for AD is safe and effective.
  • In the early phase of therapy, a higher dosage of rIFN-gamma is more effective; and for the maintenance of clinical improvement, a lower dosage of rIFN-gamma is recommended when high cost and effectiveness of rIFN-gamma are considered.
  • The therapeutic efficacy of rIFN-gamma in AD might be in part related to the decreased number of CD25(+) and EG2(+) inflammatory cells infiltrated into skin.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Dermatitis, Atopic / drug therapy. Interferon-gamma / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Biomarkers / analysis. Cost-Benefit Analysis. Cytokines / analysis. Dose-Response Relationship, Drug. Female. Humans. Immunohistochemistry. Lymphocytes / immunology. Male. Receptors, Interleukin-2 / analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Eczema.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10827410.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers; 0 / Cytokines; 0 / Receptors, Interleukin-2; 82115-62-6 / Interferon-gamma
  •  go-up   go-down

11. Sabry A, Abo-Zenah H, Medhat T, Sheashaa H, Mahmoud K, El-Huseini A: A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: an Egyptian experience. Int Urol Nephrol; 2009;41(1):153-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: In this single center, prospective clinical trial, we assigned 46 SLE patients with diffuse proliferative glomerulonephritis to either a high-dose (a maximum of 1 g/dose) of IV CYC (HD-CYC) for six monthly pulses followed by two quarterly pulses or a fixed low-dose (500 mg/dose) of IV CYC (LD-CYC) for six fortnightly pulses with a cumulative dose of 3 g.
  • THE OBJECTIVE: To compare between efficacy, potential toxicity and outcome of parenteral LD-CYC versus HD-CYC therapy for severe LN.
  • RESULTS: Twenty patients (2 male and 18 female) received fortnightly fixed LD-CYC while 26 (5 male and 21 female) received monthly HD-CYC therapy.
  • At the end of the study (1 year after starting therapy), there was no difference either in patients' or in renal survival in both groups.
  • Significant improvement of disease activity (SLE disease activity index) as well as rise of serum albumin was noticed with both regimens.
  • Renal relapse was observed in 11.5% of HD-CYC patients and in none of the LD-CYC therapy patients.
  • Treatment failure was seen in 5% and 3.4% (P = NS) of LD-CYC and HD-CYC patients, respectively.
  • Infection (pneumonia and cellulitis) occurred in five patients in the LD-CYC group and four patients of HD-CYC; again this difference was not statistically significant.
  • CONCLUSION: A remission-inducing regimen of LD-CYC (cumulative dose 3 g) followed by AZA for SLE patients with proliferative LN achieves clinical results comparable to those obtained with HD-CYC without serious infection in both regimens.
  • [MeSH-major] Cyclophosphamide / administration & dosage. Immunosuppressive Agents / administration & dosage. Lupus Nephritis / drug therapy
  • [MeSH-minor] Adult. Egypt. Female. Humans. Male. Prospective Studies. Pulse Therapy, Drug. Remission Induction

  • Genetic Alliance. consumer health - Lupus.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lupus. 1991 Nov;1(1):31-5 [1845361.001]
  • [Cites] Arthritis Rheum. 2004 Aug;50(8):2559-68 [15334470.001]
  • [Cites] Genes Immun. 2002 Oct;3 Suppl 1:S71-85 [12215907.001]
  • [Cites] Ann Intern Med. 1993 Sep 1;119(5):366-9 [8338289.001]
  • [Cites] Arthritis Rheum. 1996 Sep;39(9):1475-82 [8814058.001]
  • [Cites] Arthritis Rheum. 1991 Aug;34(8):945-50 [1859488.001]
  • [Cites] Nephrol Dial Transplant. 1997 Oct;12(10):2057-9 [9351064.001]
  • [Cites] Rheum Dis Clin North Am. 1993 Feb;19(1):263-70 [8356259.001]
  • [Cites] G Ital Nefrol. 2005 Nov-Dec;22 Suppl 33:S27-33 [16419002.001]
  • [Cites] Ann Intern Med. 1995 Nov 15;123(10):754-62 [7574193.001]
  • [Cites] Clin Exp Rheumatol. 1997 May-Jun;15(3):275-82 [9177922.001]
  • [Cites] Cochrane Database Syst Rev. 2004;(1):CD002922 [14973998.001]
  • [Cites] Arch Intern Med. 2002 Jul 22;162(14):1636-43 [12123409.001]
  • [Cites] Kidney Int. 1997 Apr;51(4):1188-95 [9083285.001]
  • [Cites] Arthritis Rheum. 2002 Apr;46(4):1003-13 [11953978.001]
  • [Cites] Am J Kidney Dis. 1997 Feb;29(2):193-9 [9016889.001]
  • [Cites] Lancet. 1992 Sep 26;340(8822):741-5 [1356175.001]
  • [Cites] J Pediatr. 1989 Jun;114(6):1055-60 [2656961.001]
  • [Cites] QJM. 1999 Apr;92(4):211-8 [10396609.001]
  • [Cites] Curr Opin Rheumatol. 2003 Sep;15(5):528-34 [12960476.001]
  • [Cites] Arthritis Rheum. 2003 Jan;48(1):166-73 [12528116.001]
  • [Cites] Clin Rheumatol. 2006 Nov;25(6):782-8 [16547692.001]
  • [Cites] Kidney Int. 2006 Aug;70(4):732-42 [16820790.001]
  • [Cites] Lupus. 2005;14(1):49-52 [15732288.001]
  • [Cites] Autoimmun Rev. 2006 Apr;5(4):269-72 [16697968.001]
  • [Cites] Lupus. 2003;12(8):640-5 [12945726.001]
  • [Cites] Am J Med. 2006 Apr;119(4):355.e25-33 [16564783.001]
  • [Cites] J Pediatr. 2000 Feb;136(2):243-7 [10657833.001]
  • [Cites] Lupus. 2005;14(1):77-82 [15732293.001]
  • [Cites] Ann Intern Med. 1996 Oct 1;125(7):549-57 [8815753.001]
  • [Cites] Am J Med. 1987 Nov;83(5):877-85 [3674094.001]
  • [Cites] Lupus. 2004;13(5):366-71 [15230294.001]
  • [Cites] J Med Assoc Thai. 1999 Nov;82 Suppl 1:S104-10 [10730528.001]
  • [Cites] N Engl J Med. 2005 Nov 24;353(21):2282-4 [16306526.001]
  • [Cites] N Engl J Med. 1986 Mar 6;314(10):614-9 [3511372.001]
  • (PMID = 18214709.001).
  • [ISSN] 1573-2584
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down

12. Kim JH, Park BL, Cheong HS, Bae JS, Park JS, Jang AS, Uh ST, Choi JS, Kim YH, Kim MK, Choi IS, Cho SH, Choi BW, Park CS, Shin HD: Genome-wide and follow-up studies identify CEP68 gene variants associated with risk of aspirin-intolerant asthma. PLoS One; 2010;5(11):e13818
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aspirin-intolerant asthma (AIA) is a rare condition that is characterized by the development of bronchoconstriction in asthmatic patients after ingestion of non-steroidal anti-inflammatory drugs including aspirin.
  • All seven SNPs of the CEP68 gene showed linkage disequilibrium (LD), and the haplotype of CEP68_ht4 (T-G-A-A-A-C-G) showed a highly significant association with aspirin intolerance (OR= 2.63; 95% CI= 1.64-4.21; P = 6.0×10(-5)).
  • [MeSH-major] Aspirin / adverse effects. Drug Hypersensitivity / genetics. Microtubule-Associated Proteins / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Adolescent. Adult. Aged. Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Asthma / drug therapy. Asthma / physiopathology. Chromosome Mapping. Female. Follow-Up Studies. Forced Expiratory Volume / drug effects. Gene Frequency. Genetic Predisposition to Disease / genetics. Genome-Wide Association Study. Genotype. Humans. Linkage Disequilibrium. Male. Middle Aged. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genetics. 1987 Oct;117(2):331-41 [3666445.001]
  • [Cites] Theor Popul Biol. 2001 Nov;60(3):155-66 [11855950.001]
  • [Cites] Clin Exp Allergy. 1997 May;27(5):574-7 [9179433.001]
  • [Cites] Lancet. 1997 Nov 29;350(9091):1599-600 [9393345.001]
  • [Cites] N Engl J Med. 1999 Jan 21;340(3):197-206 [9895400.001]
  • [Cites] Hum Mol Genet. 2004 Dec 15;13(24):3203-17 [15496426.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Nat Rev Genet. 2005 Feb;6(2):95-108 [15716906.001]
  • [Cites] Allergy. 2005 Jun;60(6):760-5 [15876305.001]
  • [Cites] Clin Exp Allergy. 2005 May;35(5):585-90 [15898979.001]
  • [Cites] Hum Genet. 2005 Jun;117(1):16-26 [15806396.001]
  • [Cites] Clin Exp Allergy. 2005 Jun;35(6):717-22 [15969660.001]
  • [Cites] Pharmacogenet Genomics. 2005 Jul;15(7):483-92 [15970796.001]
  • [Cites] Clin Exp Allergy. 2006 Apr;36(4):433-9 [16630147.001]
  • [Cites] Clin Exp Allergy. 2006 Oct;36(10):1247-53 [17014432.001]
  • [Cites] Clin Allergy Immunol. 2007;19:147-75 [17153012.001]
  • [Cites] Proteomics. 2007 Jul;7(14):2384-97 [17570516.001]
  • [Cites] Nature. 2007 Jul 26;448(7152):470-3 [17611496.001]
  • [Cites] Pharmacogenomics. 2007 Sep;8(9):1143-50 [17924829.001]
  • [Cites] J Cell Sci. 2007 Dec 15;120(Pt 24):4321-31 [18042621.001]
  • [Cites] Environ Health Perspect. 2007 Dec;115(12):1757-66 [18087596.001]
  • [Cites] Nat Rev Genet. 2008 Jun;9(6):477-85 [18427557.001]
  • [Cites] Nat Rev Drug Discov. 2008 Oct;7(10):807-17 [18806753.001]
  • [Cites] J Clin Pharm Ther. 2008 Oct;33(5):465-72 [18834360.001]
  • [Cites] Science. 2008 Nov 7;322(5903):881-8 [18988837.001]
  • [Cites] J Allergy Clin Immunol. 2000 Jul;106(1 Pt 1):72-6 [10887308.001]
  • [Cites] Chest. 2000 Nov;118(5):1470-6 [11083703.001]
  • [Cites] Annu Rev Med. 2001;52:1-14 [11160764.001]
  • [Cites] J Allergy Clin Immunol. 2001 Mar;107(3):561-2 [11240968.001]
  • [Cites] Am J Hum Genet. 2001 Apr;68(4):978-89 [11254454.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):217-22 [11586303.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Jan 1;165(1):9-14 [11779723.001]
  • [Cites] J Allergy Clin Immunol. 2002 Jun;109(6):936-42 [12063521.001]
  • [Cites] J Allergy Clin Immunol. 2003 May;111(5):913-21; quiz 922 [12743549.001]
  • [Cites] Hum Genet. 2004 Mar;114(4):337-44 [14749922.001]
  • [Cites] J Allergy Clin Immunol. 2004 Mar;113(3):562-4 [15007363.001]
  • [Cites] J Colloid Interface Sci. 2004 Sep 1;277(1):79-83 [15276041.001]
  • [Cites] Nat Rev Drug Discov. 2004 Sep;3(9):739-48 [15340384.001]
  • [Cites] J Allergy Clin Immunol. 2004 Sep;114(3):688-9 [15446291.001]
  • [Cites] Nat Genet. 2009 Mar;41(3):342-7 [19198610.001]
  • [Cites] N Engl J Med. 2009 Apr 23;360(17):1701-3 [19369656.001]
  • [Cites] N Engl J Med. 2009 Apr 23;360(17):1696-8 [19369660.001]
  • [Cites] Am J Hum Genet. 2009 May;84(5):581-93 [19426955.001]
  • [Cites] Allergy. 2009 Jun;64(6):823-39 [19416143.001]
  • [Cites] Clin Exp Allergy. 2008 Nov;38(11):1727-37 [18727619.001]
  • [Cites] Allergy. 2009 Aug;64(8):1221-5 [19222424.001]
  • [Cites] J Allergy Clin Immunol. 2009 Sep;124(3):422-7 [19665766.001]
  • [Cites] J Allergy Clin Immunol. 2009 Oct;124(4):779-85.e6 [19767079.001]
  • [Cites] Nat Rev Genet. 2010 Jun;11(6):415-25 [20479773.001]
  • [Cites] PLoS One. 2010;5(8):e11961 [20694148.001]
  • [Cites] Allergy Proc. 1993 Sep-Oct;14(5):373-6; discussion 371-2 [8288122.001]
  • (PMID = 21072201.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / CEP68 protein, human; 0 / Microtubule-Associated Proteins; R16CO5Y76E / Aspirin
  • [Other-IDs] NLM/ PMC2972220
  •  go-up   go-down

13. Ohno S, Rai Y, Iwata H, Yamamoto N, Yoshida M, Iwase H, Masuda N, Nakamura S, Taniguchi H, Kamigaki S, Noguchi S: Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). Ann Oncol; 2010 Dec;21(12):2342-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: FINDER1 compared efficacy, tolerability and pharmacokinetics (PK) of three fulvestrant dose regimens in postmenopausal Japanese women with estrogen receptor (ER)-positive locally advanced/metastatic breast cancer recurring or progressing after prior endocrine therapy.
  • PATIENTS AND METHODS: The primary end point of this randomised, multicentre, phase II study was objective response rate (ORR) and the secondary end points included time to progression (TTP), clinical benefit rate (CBR), PK profiles and tolerability.
  • Postmenopausal women with ER-positive advanced breast cancer were randomised to 28-day cycles of fulvestrant approved dose (AD), loading dose (LD) or high dose (HD) until disease progression.
  • RESULTS: Hundred and forty-three patients (median age 61 years) received fulvestrant AD (n = 45), LD (n = 51) or HD (n = 47).
  • ORR was similar across dose regimens: 11.1%, 17.6% and 10.6% for AD, LD and HD, respectively, with overlapping confidence intervals.
  • TTP and CBR were also similar between groups (median TTP: 6.0, 7.5 and 6.0 months, respectively; CBR: 42.2%, 54.9% and 46.8% for AD, LD and HD, respectively).
  • C(max) and area under the plasma concentration-time curve were dose proportional and PK steady state was reached earlier with LD and HD than with AD.
  • CONCLUSION: Fulvestrant AD, LD and HD had similar efficacy and tolerability profiles in postmenopausal Japanese women with ER-positive advanced breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. FULVESTRANT .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20494961.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 22X328QOC4 / fulvestrant; 4TI98Z838E / Estradiol
  •  go-up   go-down

14. Ma XR, Chen YX, Liu J, Zhang WG, Cao XM, He AL, Yang Y: [Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec;16(6):1312-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study was aimed to investigate the clinical efficacy and adverse reactions of different thalidomide regimens in the treatment of multiple myeloma (MM), and to explore the relationship between efficacy of thalidomide and serum level of TNF-alpha in MM patients.
  • These 5 groups were following: group with the high dose (HD-T), group with thalidomide+VAD chemotherapy (T-VAD), group with thalidomide+MP chemotherapy (T-MP), group with thalidomide plus dexamethasone (TD), and group with low dose of thalidomide (LD-T).
  • Except 5 groups mentioned above, the group with conventional VAD chemotherapy was served as the control.
  • Clinical effects, adverse reactions, treatment-related mortality were observed.
  • At the same time, serum levels of TNF-alpha in 30 cases of MM treated with thalidomide (15 cases effective and 15 cases ineffective) before and after treatment were detected by double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) and were compared with the clinical efficacy.
  • The results showed that the efficient rate of HD-T, T-VAD, T-MP, TD, LD-T groups were 25.0%, 80.0%, 71.4%, 33.3%, 27.3% respectively; the efficacy of T-VAD, T-MP groups were significantly higher (p<0.05) than that of other groups and conventional VAD chemotherapy group.
  • The treatment-related mortality was 0%.
  • At the same time, it was found that the serum levels of TNF-alpha in ineffective group treated with thalidomide were 44.7+/-5.7 pg/ml and 46.3+/-4.0 pg/ml before and after thalidomide treatment, and there was no significant difference (p>0.05).
  • The serum levels of TNF-alpha (27.3+/-6.4) pg/ml in the effective group after treatment was significantly lower than that before treatment (49.2+/-7.3) pg/ml (p<0.05).
  • It is concluded that compared with conventional chemotherapy, thalidomide is a effective drug for treating MM patients.
  • Thalidomide in combination with chemotherapy (T-VAD, T-MP) may be one better therapeutic regimen with high efficiency and milder adverse reactions.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19099634.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Comparative Study; Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tumor Necrosis Factor-alpha; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down

15. Borget I, Aupérin A, Pignon JP, Abbas M, Bouché O, Mousseau M, Raoul JL, Bedenne L, Cassan P, Clavero-Fabri MC, Stremsdoerfer N, Nasca S, Queuniet AM, Ducreux M, Fédération Francophone de Cancérologie Digestive: Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial. Oncology; 2006;71(1-2):40-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The De Gramont regimen (or high-dose LV5FU2, HD-LV5FU2) is considered a standard treatment for metastatic colorectal cancer.
  • The aim of the study was to evaluate the efficacy and the costs of three regimens as compared to HD-LV5FU2: raltitrexed (R), LV5FU2 with a lower dose of folinic acid (LD-LV5FU2), and weekly infusional 5FU (WI-FU).
  • METHODS: An economic analysis was performed prospectively as part of a randomized trial comparing first-line chemotherapy regimens in 294 patients with unresectable metastatic colorectal cancer.
  • RESULTS: None of the three regimens improved EFS as compared to HD-LV5FU2.
  • The mean total cost per patient was euro 15,970 for HD-LV5FU2.
  • The cost of R (10,687 euro) was lower than that of HD-LV5FU2 (p = 0.008).
  • The cost of LD-LV5FU2 (14,888 euro) and of WI-FU (13,760 euro) was not significantly different from that of HD-LV5FU2.
  • The HD-LV5FU2 protocol remains a better treatment.
  • LD-LV5FU2 appeared a good alternative regimen because it reduced costs without jeopardizing its efficacy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Cost of Illness. Cost-Benefit Analysis. Disease-Free Survival. Female. France. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Staging. Quinazolines / administration & dosage. Survival Rate. Thiophenes / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17344670.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Quinazolines; 0 / Thiophenes; FCB9EGG971 / raltitrexed; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down

16. Wexberg P, Sperker W, Morgenthaler NG, Heinzl H, Adlbrecht C, Plass C, Glogar HD, Lang IM, Neunteufl T: Inhomogeneous vasomotor effects of moderate selective and non-selective endothelin-receptor blockade in stable coronary artery disease. Heart; 2009 Aug;95(15):1258-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhomogeneous vasomotor effects of moderate selective and non-selective endothelin-receptor blockade in stable coronary artery disease.
  • OBJECTIVE: To explore the morphological and functional effect of selective and non-selective endothelin (ET)-receptor blockade in coronary artery disease (CAD).
  • MAIN OUTCOME MEASURES: Fractional flow reserve (FFR), coronary flow reserve (CFR) and intramyocardial resistance (IMR) by PressureWire, mean arterial blood pressure (MAP), minimal lumen diameter (MLD) and average angiographic lumen diameter (mean LD) of the target vessel before and after intracoronary infusion of ET antagonists.
  • RESULTS: Mean MLD, mean LD, FFR, CFR, IMR and MAP remained unaffected by ET-receptor blockade in both groups; their changes were comparable.
  • Prolonged infusion time may be needed to cause a more distinct vasomotor response.
  • [MeSH-major] Antihypertensive Agents / therapeutic use. Coronary Artery Disease / drug therapy. Endothelin Receptor Antagonists. Oligopeptides / therapeutic use. Peptides, Cyclic / therapeutic use. Piperidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Angina Pectoris / drug therapy. Angina Pectoris / physiopathology. Coronary Angiography. Endothelin-1 / blood. Female. Fractional Flow Reserve, Myocardial / drug effects. Humans. Male. Middle Aged. Myocardial Ischemia / drug therapy. Myocardial Ischemia / physiopathology. Prospective Studies. Protein Precursors / blood. Young Adult

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414437.001).
  • [ISSN] 1468-201X
  • [Journal-full-title] Heart (British Cardiac Society)
  • [ISO-abbreviation] Heart
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00427232
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 0 / BQ 788; 0 / Endothelin Receptor Antagonists; 0 / Endothelin-1; 0 / Oligopeptides; 0 / Peptides, Cyclic; 0 / Piperidines; 0 / Protein Precursors; 0 / proendothelin 1; 136553-81-6 / cyclo(Trp-Asp-Pro-Val-Leu)
  •  go-up   go-down

17. Lehmann KA, Paral F, Sabatowski R: [Postoperative pain therapy with hydromorphone and metamizole. A prospective randomized study in intravenous patient-controlled analgesia (PCA)]. Anaesthesist; 2001 Oct;50(10):750-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative pain therapy with hydromorphone and metamizole. A prospective randomized study in intravenous patient-controlled analgesia (PCA)].
  • [Transliterated title] Postoperative Schmerztherapie mit Hydromorphon und Metamizol. Eine prospektiv randomisierte Untersuchung im Rahmen der intravenösen patientenkontrollierten Analgesie (PCA).
  • A total of 120 patients recovering from elective abdominal or orthopaedic surgery, performed under standardised general anaesthesia, were randomised into 3 double-blind treatment groups to receive intravenous PCA demand doses of hydromorphone 283 micrograms (low dose, LD), 566 micrograms (high dose, HD) or a combination of hydromorphone 283 micrograms and metamizole 50 mg (low dose hydromorphone + metamizole, LM).
  • Lockout times were set to 2 min.
  • After an average observation time of 24.5 +/- 2.6 h (mean, SD) since start of PCA, cumulative PCA hydromorphone doses in groups LD, HD and LM were 7.8 +/- 3.3, 12.1 +/- 4.8 and 7.5 +/- 2.0 mg, respectively, with the well known large inter-individual variability in all groups.
  • Although hydromorphone consumption was significantly higher in group HD, self-reported pain intensities (VAS, retrospective pain scores) were quite comparable between the groups.
  • Side-effects were typical for potent postoperative opioids, but never required special treatment; haemodynamic or respiratory complications were not observed in any patient.
  • It can be concluded by comparison with other PCA opioid investigations performed under the same study protocol that hydromorphone is about 3-4 times as potent an analgesic as morphine under the conditions of intravenous postoperative PCA.
  • Due to a favourable patient acceptance, hydromorphone can be recommended as a suitable alternative to other opioids for the treatment of postoperative pain.
  • [MeSH-major] Analgesia, Patient-Controlled. Analgesics, Opioid / therapeutic use. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Dipyrone / therapeutic use. Hydromorphone / therapeutic use. Pain, Postoperative / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Double-Blind Method. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Prospective Studies

  • Hazardous Substances Data Bank. HYDROMORPHONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11702324.001).
  • [ISSN] 0003-2417
  • [Journal-full-title] Der Anaesthesist
  • [ISO-abbreviation] Anaesthesist
  • [Language] ger
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Anti-Inflammatory Agents, Non-Steroidal; 6429L0L52Y / Dipyrone; Q812464R06 / Hydromorphone
  •  go-up   go-down

18. Cerfolio RJ, Bryant AS, Spencer SA, Bartolucci AA: Pulmonary resection after high-dose and low-dose chest irradiation. Ann Thorac Surg; 2005 Oct;80(4):1224-30; discussion 1230
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The purpose of this study is to assess the safety and efficacy of pulmonary resection after low and high dose neoadjuvant radiotherapy with concurrent chemotherapy.
  • All patients had N2, stage IIIa, nonsmall cell lung cancer, and received neoadjuvant carboplatinum-based chemotherapy with similar doses.
  • In addition, some patients received high-dose chest radiation (HD) equal to or greater than 60 Gy and were compared with those who received low-dose radiation (LD) less than 60 Gy.
  • RESULTS: There were 104 patients, 50 in the LD group and 54 patients in the HD group.
  • Median dose of radiation was 45 Gy (range 35-50.4) in the LD group and 60 Gy (range 60-66.7) in the HD group.
  • Complete pathologic response rate was 10% compared to 28% favoring the HD group (p = 0.04).
  • CONCLUSIONS: Pulmonary resection after preoperative chest radiation is safe even after 60 Gy or higher.
  • However, if pneumonectomy is known to be required we prefer to avoid neoadjuvant radiotherapy and use chemotherapy alone.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / radiotherapy. Lung Neoplasms / surgery. Neoadjuvant Therapy / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Cohort Studies. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pneumonectomy. Radiotherapy Dosage. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16181844.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down

19. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Cauli A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis; 2010 Jan;69(1):61-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To update the follow-up of the Euro-Lupus Nephritis Trial (ELNT), a randomised prospective trial comparing low-dose (LD) and high-dose (HD) intravenous (IV) cyclophosphamide (CY) followed by azathioprine (AZA) as treatment for proliferative lupus nephritis.
  • RESULTS: Death, sustained doubling of serum creatinine and end-stage renal disease rates did not differ between the LD and HD group (5/44 (11%) vs 2/46 (4%), 6/44 (14%) vs 5/46 (11%) and 2/44 (5%) vs 4/46 (9%), respectively) nor did mean serum creatinine, 24 h proteinuria and damage score at last follow-up.
  • Most patients in both groups were still treated with glucocorticoids, other immunosuppressant agents and blood pressure lowering drugs.
  • After 10 years of follow-up, the positive predictive value for a good outcome of an early drop in proteinuria in response to initial immunosuppressive therapy was confirmed.
  • CONCLUSION: The data confirm that a LD IVCY regimen followed by AZA-the "Euro-Lupus regimen"-achieves good clinical results in the very long term.
  • [MeSH-major] Cyclophosphamide / administration & dosage. Immunosuppressive Agents / administration & dosage. Lupus Nephritis / drug therapy
  • [MeSH-minor] Adolescent. Adult. Azathioprine / therapeutic use. Dose-Response Relationship, Drug. Drug Therapy, Combination. Epidemiologic Methods. Female. Humans. Injections, Intravenous. Kidney Function Tests. Male. Middle Aged. Proteinuria / drug therapy. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Lupus.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155235.001).
  • [ISSN] 1468-2060
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; MRK240IY2L / Azathioprine
  •  go-up   go-down

20. Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, Lam A, Villalobos Vega JC, Cuéllar JA, de Castro FJ, Quintero CM, Martíin JF, Domínguez P, Ojeda JL, Cortés SS, Cala FI, Marín CG, Castro LM, Duaso MA, Albarracín JR, Vergara GN, Benítez AF, Cleries FM, Pérez-Brian JM, Aragón AB, Navarro JC, Biedma JA, de Pedro RB, González JF, López ME, Moreno HD, López JA, Rodríguez EO, de Hoyos CM, Sacristán MP, Martín MD, Ballesteros EM, Rodríguez PA, Menéndez LF, Rivas RS, del Pino Cuadrado P, Lauffer JC, Solano JJ, Martínez JM, Solano FG, Rodríguez PG, Rodríguez JA, Cano TR, Fortacin MD, Lobeiras JM, Sampedro JM, Bravo AP, Pellicer AF, López MD, Liste JF, Fernández MR, Losada AC, Mendez RV, Romero SA, Blanco JJ, Bonaselt IT, Mahia MC, del Valle EF, Yañez PQ, Camarasa MG, Alonso JA, Mendez GF, Feliz FD, Lamela MA, Piñero MV, Alvarado PF, Gómez IL, Martín PF, Gómez JL, López AG, Jiménez AR, Nafs AE, Barquero NC, Ortiz RF, Noguera JL, Carrasco PR, Muñoz JM, Palma MM, Hortelano CM, Bonome LS, Sevilla JS, Juan JM, Ramos JM, Muñoz JL, Guisasola JE, Vazquez LS, Guerras FC, Nebot FJ, Fernández FJ, Nicolau AL, Subirats RC, Kidias MM, Navarro VF, García BF, del Rosal FM, de Vicente Muñoz T, Ballester JA, Lieb PM, Martel AD, Bea ER, Joaquim IG, Enjuanes FB, Piñol MB, Carbonell EF, Muñoz RM, Giribets CA, Sans LA, Blanco AS, Felipe MA, Muñoz PG, Villanueva AP, Arroyo MB, Borri RC, Fallada SM, Merola MC, Rodon EP, Palmes JR, Martínez EP, Catala JM, Coca AS, Ferrandiz FP, Paya EF, Caballero GI, Bonet AF, Figueras JF, Pagador PM, Garibo MM, Camo VP, Carrillo CS, Valero CP, Rebollo FJ, García Campayo J, Sala Ayma JM, Roig MM, de Uña Mateos MA, Bertolin RG, García AM, Mazo FJ, Velasco JL, Pérez LS, Casado CJ, Barba JJ, Diaz MC, Rubio JP, Mandoli AS, Herrero AU, Martínez AR, Serrano PS, Rodríguez EN, Montesinos JS, Macia JF, Mateos Marcos AM, Soto JV, Dumont MV, Pagan JP, Martínez VB, Santiuste de Pablos M, Delgado CE, Quiles MD, López FJ, Navarro PP, Torres AM, Ingles FJ, Arias-Camison JM, Manzano JC, Peña RV, Guitarte GP, Fontecilla HB, Romero JB, Gil RS, Lozano JM, Adanez LD, Zarranz Herrera-Oria I, Jiménez JP, Vaz FC, García OS, Anton CC, Casula RR, Hernandez MC, Escabias FT, Torresano JR, Pérez-Villamil AH, Estevez L, Figuero MA, Muñoz de Morales A, Calvin JL, Criado MD, Rodríguez VM, Ambrosolio EB, Madera PM, Alfaro GP, Vidal MM, Valtuille AG, Ruiz O, Cabornero GL, Echevarria Martínez de Bujo M, Mallen MJ, Puigros JS, Martorell AL, Forteza AC, Arrebola ER, Rodríguez de la Torre M, Saiz CG, Bardolet I Casas C, Linde ER, De Arce Cordon R, Molina EM, Carazo FJ, Romero JJ, Cano DV, Dorado MS, Velazquez SC, Sánchez AJ, Leon SO, Sánchez KP, Benitez MH, Zugarramurai AI, Contreras MA, De la Varga González M, Marín PB, Robina FG, García MS, Pérez FJ, Bros PC, Gómez AC, de Dios Molina Martín J, Perera JL, Averbach MC, Perera JL, Palancares EG, Gallego de Dios MT, Rojo CF, Iglesias SS, Merino MI, Mestre NP, Urdaniz AP, Sánchez JM, Seco RG, Muñoz JF, Agut MM, Lozano ML, Herguedas FM, Pena AT, García JV, Martínez AV, Sanz Granado OS, Fernández MA, Canseco JM, López PA, Martín MA, Barrio JA, Ubago JG, Bennassar MR, Díez JM, Fleta JL, Fortes FP, López CA, Medina O, Alvarez DF, Roca JM, Valladolid GR, Tavera JA, García-Castrillon Sales JA, Llordes IB, Melgarejo CA, Cañas de la Paz F, Callol VV, García MB, García JB, Leal FJ, Corrales EC, Iglesias ES, Gómez MA, Serrano GG, Chillarón EG, Aguado FJ, Castillo JJ, González AG, Vázquez JG, Peralvarez MB, Diaz MR, Mesa MY, Artiles FJ, Chao MA, Mesa MY, del Rosario Santana P, Escudero MA, Berenguer MM, Llacer JM, Berna JA, Ortiz JB, Pardell LT, Hernández-Alvarez de Sotomayor C, Méndez MR, Garate RC, Múgica BD, González MC, Domingo JP, Navarro CS, Vera GS, Cuquerella MA, Monzo JL, Boada PC, Pérez MF, Parrado EC, Sánchez JJ, Fernández JC, e-STAR Spanish Study Group: Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry; 2009 Jun;24(5):287-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).
  • BACKGROUND: The electronic Schizophrenia Treatment Adherence Registry (e-STAR) is a prospective, observational study of patients with schizophrenia designed to evaluate long-term treatment outcomes in routine clinical practice.
  • Hospitalization prior to therapy was assessed by a retrospective chart review.
  • RESULTS: At 24 months, treatment retention (81.8% for RLAI versus 63.4% for oral APs, p<0.0001) and reduction in Clinical Global Impression Severity scores (-1.14 for RLAI versus -0.94 for APs, p=0.0165) were significantly higher with RLAI.
  • CONCLUSIONS: This 2 year, prospective, observational study showed that, compared to oral antipsychotics, RLAI was associated with better treatment retention, greater improvement in clinical symptoms and functioning, and greater reduction in hospital stays and days in hospital in patients with schizophrenia.
  • Improved treatment adherence, increased efficacy and reduced hospitalization with RLAI offer the opportunity of substantial therapeutic improvement in schizophrenia.
  • [MeSH-major] Antipsychotic Agents / administration & dosage. Medication Adherence. Risperidone / administration & dosage. Schizophrenia / drug therapy. Schizophrenic Psychology
  • [MeSH-minor] Administration, Oral. Adult. Benzodiazepines / administration & dosage. Benzodiazepines / adverse effects. Delayed-Action Preparations. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Injections, Intramuscular. Long-Term Care. Male. Middle Aged. Patient Readmission / statistics & numerical data. Prospective Studies. Psychiatric Status Rating Scales. Registries

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • Hazardous Substances Data Bank. RISPERIDONE .
  • Hazardous Substances Data Bank. Olanzapine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19195847.001).
  • [ISSN] 0924-9338
  • [Journal-full-title] European psychiatry : the journal of the Association of European Psychiatrists
  • [ISO-abbreviation] Eur. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Delayed-Action Preparations; 12794-10-4 / Benzodiazepines; 132539-06-1 / olanzapine; L6UH7ZF8HC / Risperidone
  •  go-up   go-down